METHODS OF ALTERING PROTEIN DEPOSITION ON URINARY CATHETERS AND DEVICES
20240033403 ยท 2024-02-01
Inventors
- Caitlin Lake Howell (Veazie, ME, US)
- Marissa J. Andersen (South Bend, IN, US)
- Ana Lidia Flores Mireles (South Bend, IN, US)
Cpc classification
A61L29/06
HUMAN NECESSITIES
A61L2300/404
HUMAN NECESSITIES
International classification
Abstract
Presented herein are devices, systems, and methods related to liquid infused substrates for use in medical applications. Adhesion of proteins, pathogens, and other substances to medical devices presents an issue. Proteins from the surrounding environment adhere to medical devices, which may, under certain conditions, result in the adhesion of pathogens to the medical device. The presence of these pathogens may result in infections when a medical device is inserted or otherwise placed in vivo (in whole or in part), which may require the removal of the device and/or treatment of the subject with antibiotics. Changing the surface properties of such devices can alter which proteins, pathogens, and/or other substances adhere and/or adsorb to the surface. Accordingly, in some embodiments, the present disclosure provides for technologies for altering surface adhesion and/or absorption of proteins, pathogens and/or other substances by infusing/impregnating a substrate of the device with an impregnation fluid.
Claims
1. A method of modifying a polymeric substrate of a medical device, the method comprising: infusing the polymeric substrate with an impregnation fluid such that the polymeric substrate is impregnated with the impregnation fluid.
2. The method of claim 1, wherein the polymeric substrate is biocompatible.
3. The method of claim 1, wherein the polymeric substrate comprises silicone.
4. The method of claim 3, wherein the silicone comprises polydimethylsiloxane (PDMS).
5. The method of claim 1, wherein the polymeric substrate comprises a hydrogel, poly(acrylic acid), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethylene glycol), polyacrylamide, or a polysaccharide hydrogel.
6. The method of claim 1, wherein the impregnation fluid comprises a hydrophilic liquid or a hydrophilic ionic liquid.
7. The method of claim 1, wherein the polymeric substrate comprises an organogel.
8. The method of claim 7, wherein the organogel comprises one or more of the following materials: anthracene, anthraquinone and steroid-based molecules.
9. The method of claim 1, wherein the impregnation fluid is silicone oil.
10. (canceled)
11. The method of claim 9, wherein the viscosity of the silicone oil is from 0.65 cSt to 10,000 cSt.
12.-13. (canceled)
14. The method of claim 1, wherein the impregnation fluid comprises one or more of the following: low-volatility polydimethylsiloxanes, cyclic polydimethylsiloxanes, silicone emulsions, silicone fluid blends, thermal silicone fluids, alkyl silicones, aryl-alkyl silicones, fluorosilicone fluids, hydrophilic silicones, polar silicones, ampliphilic silicones, low-temperature fluids, and naturally derived silicones.
15. The method of claim 9, wherein the method comprises removing substantially all of the free silicone oil from a surface the polymeric substrate.
16. The method of claim 15, wherein the method comprises mechanically or chemically removing post-infusion excess silicone oil from the surface of the polymeric substrate.
17. The method of claim 9, wherein the method does not produce an immobilized liquid layer of silicone on the surface of the polymeric substrate.
18. (canceled)
19. The method of claim 9, wherein infusing the polymeric substrate with the silicone oil comprises impregnating the polymeric substrate from 50% to 99.99% of the maximum absorption capacity of the polymeric substrate.
20-21. (canceled)
22. The method of claim 1, wherein the method reduces adhesion and/or adsorption of one or more protein(s) to a surface of the polymeric substrate.
23. The method of claim 22, wherein the one or more protein(s) comprise fibrinogen or serum albumin.
24. The method of claim 1, wherein the method increases adhesion and/or adsorption of one or more protein(s) to the polymeric substrate.
25. The method of claim 24, wherein the one or more protein(s) comprises one or more members of the group consisting of: UDP-glucose 6-dehydrogenase (UGDH), filamin B (FLNB), and Proteasome 20S Subunit Beta 5 (PSMB5).
26. (canceled)
27. The method of claim 1, wherein the polymeric substrate comprises an outward facing surface which interfaces with a tissue.
28. The method of claim 1, wherein the polymeric substrate comprises an inward facing surface which interfaces with a biological fluid.
29.-30. (canceled)
31. A method of modifying a urinary catheter to alter protein adhesion to a polymeric substrate of the catheter, the method comprising: infusing, by immersion for a period of time, the polymeric substrate of the urinary catheter with a silicone oil, wherein the polymeric substrate comprises silicone, wherein the period of time is characterized in that the polymeric substrate is impregnated with the silicone oil; and removing substantially all of the silicone oil from the surface(s) of the polymeric substrate such that the surface(s) of the polymeric substrate does not comprise free silicone oil.
32. (canceled)
33. A medical device comprising: a polymeric substrate, wherein the polymeric substrate is infused with an impregnation fluid.
34.-59. (canceled)
Description
BRIEF DESCRIPTION OF THE FIGURES
[0051] Drawings are presented herein for illustration purposes, not for limitation. The foregoing and other objects, aspects, features, and advantages of the disclosure will become more apparent and may be better understood by referring to the following description taken in conjunction with the accompanying drawings.
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088] The features and advantages of the present disclosure will become more apparent from the detailed description set forth below when taken in conjunction with the drawings, in which like reference characters identify corresponding elements throughout. In the drawings, like reference numbers generally indicate identical, functionally similar, and/or structurally similar elements.
DEFINITIONS
[0089] About: The term about, when used herein in reference to a value, refers to a value that is similar, in context to the referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by about in that context. For example, in some embodiments, the term about may encompass a range of values that within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.
[0090] Alkyl: As used herein, the term alkyl is given its ordinary meaning in the art and may include saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In some embodiments, alkyl has 1-100 carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has about 1-20 carbon atoms in its backbone (e.g., C1-C20 for straight chain, C2-C20 for branched chain), and alternatively, about 1-10. In some embodiments, a cycloalkyl ring has from about 3-10 carbon atoms in their ring structure where such rings are monocyclic or bicyclic, and alternatively about 5, 6 or 7 carbons in the ring structure. In some embodiments, an alkyl group may be a lower alkyl group, wherein a lower alkyl group comprises 1-4 carbon atoms (e.g., C1-C4 for straight chain lower alkyls).
[0091] Aryl: The term aryl used alone or as part of a larger moiety as in aralkyl, aralkoxy, or aryloxyalkyl, refers to ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term aryl may be used interchangeably with the term aryl ring. In certain embodiments of the present invention, aryl refers to an aromatic ring system and exemplary groups include phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term aryl, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
[0092] Biocompatible: The term biocompatible, as used herein, refers to materials that do not cause significant harm to living tissue when placed in contact with such tissue, e.g., in vivo. In certain embodiments, materials are biocompatible if they are not toxic to cells. In certain embodiments, materials are biocompatible if their use in vivo does not induce significant inflammation or other such adverse effects.
[0093] Impregnate: The term impregnate as used herein refers to infusing a material with a fluid such that it swells the material. In certain embodiments, a material is partially impregnated with a fluid. In certain embodiments, a material is fully impregnated with a fluid. Exemplary materials and impregnation fluids are described herein. In certain embodiments, the degree of impregnation of a material is measured based on the relative amount of fluid (e.g., an impregnation fluid) the material absorbs or infused with. In certain embodiments, impregnation occurs through diffusion of an impregnation fluid into a substrate.
[0094] Absorption Capacity: The term absorption capacity is used to describe the amount of an impregnation fluid that can be absorbed by or infused into a substrate. In certain embodiments, the absorption capacity of a material is dependent on the material and/or methods used to impregnate a material with a fluid. For example, the temperature of the substrate and/or impregnation fluid, viscosity of the impregnation fluid, cross-linking density of the substrate, composition of the impregnation fluid, composition of the substrate, period of time of infusion of the impregnation fluid, and other factors (e.g., as disclosed herein) may alter the absorption capacity. In certain embodiments, Q.sub.max is a ratio of the difference between the mass of the material when substantially fully infused (M.sub.swollen) with an impregnation fluid and the original mass of the material (M.sub.Original) to the original mass of the material (M.sub.Original)
In certain embodiments, Q.sub.max is measured at ambient room temperature (e.g., about 25 C.) and pressure (e.g., about 1013.25 hPa). In certain embodiments, the absorption capacity is expressed as a percentage of Q.sub.max where 0% Q.sub.max is indicative of the material having not been infused with the impregnation fluid and 100% Q.sub.max is indicative of the material having been substantially completely infused with the impregnation fluid.
[0095] Substantially: As used herein, the term substantially refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term substantially is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
DETAILED DESCRIPTION
[0096] It is contemplated that systems, devices, methods, and processes of the claimed invention encompass variations and adaptations developed using information from the embodiments described herein. Adaptation and/or modification of the systems, devices, methods, and processes described herein may be performed, as contemplated by this description.
[0097] Throughout the description, where articles, devices, and systems are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are articles, devices, systems, and architectures of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
[0098] It should be understood that the order of steps or order for performing certain action is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be conducted simultaneously.
[0099] The mention herein of any publication, for example, in the Background section, is not an admission that the publication serves as prior art with respect to any of the claims presented herein. The Background section is presented for purposes of clarity and is not meant as a description of prior art with respect to any claim.
[0100] Documents are incorporated herein by reference as noted. Where there is any discrepancy in the meaning of a particular term, the meaning provided in the Definition section above is controlling.
[0101] Headers are provided for the convenience of the readerthe presence and/or placement of a header is not intended to limit the scope of the subject matter described herein.
[0102] The technologies presented herein relate to are devices, systems, and methods related to substrates infused with an impregnation fluid for use in medical applications. Deposition of material (e.g., proteins) on a surface of a substrate (e.g., a polymeric substrate) of a medical device occurs when a medical device is implanted into a subject. Infusing a substrate with an impregnation fluid results in alterations to surface properties of the substrate. In certain embodiments, the technologies disclosed herein relate to infusing a substrate with an impregnation fluid such that there is no overlayer of or excess impregnation fluid present on a surface of the substrate. Excess impregnation fluid on a surface could lead to substantially total inhibition of all proteins or materials onto a surface.
[0103] New and current management guidelines for CAUTIs have resulted in moderate reductions in incidences. The standard treatment for patients with symptomatic CAUTI is catheter removal and replacement and an antibiotic regiment. However, this approach is not effective because biofilms on the catheter surface protect microbes against antibiotics and the immune system. Additionally, there is a potential development of antimicrobial resistance. Catheters impregnated with antimicrobials, such as metal ions and antibiotics, have become popular and are now commercialized due to promising in vitro work but, in clinical trials these catheters have shown, at best, mixed results. Importantly, there is concern that this approach may not be a long-term solution given that the presence of antimicrobial compounds may drive development of resistance, especially when considering the host factors that coat urinary catheters could potentially inhibit or decrease pathogen interaction with antimicrobials.
[0104] Microbial adhesion to medical devices is common for hospital-acquired infections, including for urinary catheters. If not properly treated these infections cause complications and exacerbate antimicrobial resistance. Catheter use elicits bladder inflammation, releasing host serum-proteins, including fibrinogen (Fg), into the bladder, which deposit on the urinary catheter. E. faecalis uses fibrinogen as a scaffold to bind and persist in the bladder despite antibiotic treatments. Inhibition of fibrinogen-pathogen interaction significantly reduces infection.
[0105] Host clotting factor 1, fibrinogen (Fg), (a host glycoprotein) is important for surface adhesion and subsequent establishment of biofilms and persistence of CAUTIs in E. faecalis and Staphylococcus aureus infections. Targeting catheter protein deposition may reduce pathogen (e.g., uropathogen) colonization, creating an effective intervention. Fg is continuously released into the bladder lumen in response to mechanical damage to the urothelial lining caused by catheterization. Once in the lumen, Fg is deposited on the catheter, providing a platform for incoming uropathogens to attach and form biofilms. Biofilms are the most common underlying cause of bacteriuria and play an important role in promoting bladder colonization, microbial persistence, and systemic dissemination.
I. Methods of Infusion of a Substrate with an Impregnation Fluid
[0106] Technologies described herein relate to methods and systems for infusing a substrate with an impregnation fluid. In some embodiments, a substrate can be impregnated partially (e.g., less than 100%) with an impregnation fluid. In some embodiments, a substrate can be impregnated 99% or less with an impregnation fluid (e.g., 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 50% or less). In certain embodiments, a substrate can be impregnated more than 1% with an impregnation fluid (e.g., 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more. 80% or more, 85% or more, 90% or more, 99.9% or more). In some embodiments, a substrate can be impregnated with from 1% to 99.9% with an impregnation fluid (e.g., from 50% to 99.9%, from 55% to 99.9%, from 60% to 99.9%, from 65% to 99.9%, from 70% to 99.9%, from 75% to 99.9%, from 85% to 99.9%, from 90% to 99.9%, from 1% to 90%, from 50% to 90%, from 55% to 90%, from 60% to 90%, from 65% to 90%, from 70% to 90%, from 85% to 90%, from 1% to 85%, from 50% to 85%, from 55% to 85%, from 60% to 85%, from 65% to 85%, from 70% to 85%, from 75% to 85%, from 80% to 85%, from 1% to 80%, from 50% to 80%, from 55% to 80%, from 60% to 80%, from 65% to 80%, from 70% to 80%, from 75% to 80%, from 1% to 75%, from 50% to 75%, from 55% to 75%, from 60% to 75%, from 65% to 75%, from 70% to 75%, from 1% to 70%, from 50% to 70%, from 55% to 70%, from 60% to 70%, from 65% to 70%, from 1% to 65%, from 50% to 65%, from 55% to 65%, from 60% to 65%, from 1% to 60%, from 50% to 60%, from 55% to 60%, from 1% to 55%, from 50% to 55%, from 1% to 50%).
[0107] In certain embodiments, a substrate can be infused from 90% to 99% with an impregnation fluid. In some embodiments, a maximum adhesion reduction (e.g., of proteins) with a minimal or substantially no impregnation fluid (e.g., silicone oil) overlayer occurs from to 95% impregnation.
[0108] In some embodiments, the degree of impregnation (e.g., percent impregnation, e.g., % Q.sub.max) for a given substrate is determined based on how much of an impregnation fluid is infused into a substrate. A change in mass of a substrate after infusion with an impregnation fluid can be used to determine the degree of impregnation. In some embodiments, the maximum amount of material that can be infused (e.g., 100% impregnated or substantially completely impregnated) into a substrate can be determined by monitoring the change in mass or weight of the substrate over time during the infusion process. In certain embodiments, for example, full impregnation is determined by measuring changes in mass or weight of a substrate and determining that no further, substantial changes in weight are observed. In certain embodiments, a fully impregnated substrate changes less than 10% (e.g., less than 5%, less than 1%) between weight measurements.
[0109] In certain embodiments, Q.sub.max is a maximum absorption capacity of a substrate. That is, Q.sub.max is an amount of impregnation fluid that is substantially the maximum amount of impregnation fluid that can be infused for a given infusion method, infusion conditions, or period of time. Q.sub.max is determined using the following equation:
Q.sub.max=(M.sub.1M.sub.0)/M.sub.0
[0110] where M.sub.1 is a mass of the given material after having been fully impregnated and M.sub.0 is the initial mass of the material. In certain embodiments, the absorption capacity of a substrate can be expressed as a percentage of Q.sub.max.
[0111] In certain embodiments, Q.sub.max can be calculated as the amount of impregnation fluid absorbed by a substrate such that no significant changes in mass of an impregnated substrate are observed over a given period of time. For example, Q.sub.max can be determined after relatively little to no change is observed in the mass of the substrate undergoing or having undergone infusion.
[0112] Infusing a substrate with an impregnation fluid can involve immersing or submerging a substrate in an impregnation fluid for a time period. In certain embodiments, a substrate is a polymeric (e.g., a cross-linked) substrate that is immersed in an impregnation fluid (e.g., silicone oil). In certain embodiments, a time period is at least 1 minute (e.g., at least 5 minutes, at least, 10 minutes, at least 30 minutes, at least 1 hour, at least 15 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 5 days or more). In certain embodiments, a time period is dependent on the degree of impregnation desired. In certain embodiments, a time period is determined based on one or more physical properties of a substrate. For example, without limitation, substrate thickness, substrate density (e.g., crosslinking density), temperature (e.g., of an impregnation fluid), and substrate composition may effect infusion time and a rate at which a substrate is infused with an impregnation fluid.
[0113] In certain embodiments, infusing a substrate with an impregnation fluid results in an overlayer or immobilized layer of impregnation fluid on a surface of the substrate. In some embodiments, a substrate can be impregnated (e.g., fully or partially impregnated) with an impregnation fluid such that an overlayer of fluid or immobilized layer of fluid is created on a surface of the substrate due to infusion. As discussed herein, in certain embodiments. the presence of an overlayer or immobilized fluid layer is undesirable as it prevents the adhesion of substantially any proteins to surfaces of an impregnated substrate. Additionally, an overlayer of impregnation fluid may leach into a subject into which a substrate is implanted, resulting in negative effects on the health or a condition of the subject.
[0114] In certain embodiments, an overlayer or an immobilized or overlayer of impregnation fluid is removed from a surface of a substrate after infusion of the substrate with the impregnation fluid. In certain embodiments, an immobilized fluid or overlayer is removed mechanically and/or chemically from a substrate. In certain embodiments, mechanical removal of an overlayer or immobilized fluid layer involves contacting a surface of a substrate with a suitable device or implement to physically wipe the surface of the device. For example, in some embodiments, a surface of a substrate is wiped with an absorbent material (e.g., a Kimwipe) to remove excess or immobilized fluid from a surface of an impregnated substrate. In some embodiments, mechanical removal results in removal of substantially all of the immobilized or excess impregnation fluid from a surface of a substrate. In certain embodiments, chemical removal of an overlayer or immobilized fluid layer results in dissolution of an overlayer or immobilized fluid layer (e.g., substantially complete dissolution of an overlayer or immobilized fluid layer). In certain embodiments, a solvent is used to chemically remove an overlayer or immobilized fluid layer. In certain embodiments, a solvent is any suitable solvent for dissolution of an overlayer or immobilized fluid layer. Based on the present disclosure, a person of skill in the art would understand solvents for dissolution of an overlayer or immobilized fluid layer.
II. Impregnation Fluids
[0115] An impregnation fluid is any suitable fluid which can be infused (e.g., by diffusion) into a substrate in order to create a desired effect on absorption or adhesion to a surface of a substrate. In certain embodiments, an impregnation fluid is biocompatible (e.g., medical grade).
[0116] In certain embodiments, an impregnation fluid is or comprises a silicone oil (e.g., when the substrate is a polymeric substrate, e.g., PDMS). In certain embodiments, the viscosity of a silicone oil is greater than 0.65 cSt (e.g., greater than 10 cSt, greater than 50 cSt, greater than 1000 cSt). In certain embodiments, the viscosity of a silicone oil is less than 10,000 cSt (e.g., less than 1000 cSt, less than 50 cSt, less than 10 cSt). In certain embodiments, the viscosity of a silicone oil is from 0.65 cSt to 10,000 cSt (e.g., from 0.65 cSt to 1000 cSt, from 0.65 cSt to 50 cSt, from 0.65 cSt to 10 cSt, from 10 cSt to 1000 cSt, from 10 cSt to 50 cSt, from 50 cSt to 1000 cSt, from to 10,000 cSt, from 1000 cSt to 10,000 cSt). In certain embodiments, the viscosity of a silicone oil is about 50 cSt. In certain embodiments, the viscosity is a kinematic viscosity of the fluid. In certain embodiments, the viscosity of a silicone oil is measured using a viscometer (e.g., a u-tube viscometer, a falling-sphere viscometer, a vibrational viscometer, a rotational viscometer, an electromagnetically spinning-sphere viscometer). In certain embodiments, the viscosity is measured at about 25 C. using a viscometer.
[0117] In certain embodiments, an impregnation fluid comprises low-volatility polydimethylsiloxanes, cyclic polydimethylsiloxanes (e,g, cyclomethicones), silicone emulsions, silicone fluid blends, thermal silicone fluids, organic compatible silicone fluids (e.g., alkyl silicones (e.g., alkyl-methylsiloxane fluids), aryl-alkyl silicones), fluorosilicones, hydrophilic silicones (e.g. polyalkylene oxide silicones), polar silicones, ampliphilic silicones, low-temperature fluids (e.g. polydiethysiloxanes, silahydrocarbons, branched fluids, disiloxanes, trisiloxane fluids), naturally derived silicones (e.g., MonoAnisyl-terminated polydimethylsiloxane, limonenyl trisiloxane). In certain embodiments, a silicone oil comprises trimethoxy terminated polydimethylsiloxane. In certain embodiments, a silicone oil comprises repeating siloxane units and end-blocking siloxane units.
[0118] In certain embodiments, a silicone oil is a medical grade silicone oil. In some embodiments, the silicone oil comprises a silicone oil that is or is an equivalent of a Liveo360 Medical Fluid. For example, without limitation, a silicone oil has a viscosity of about 20 cSt, 100 cSt, about 350 cSt, about 1000 cSt, or about 23,500 cSt. In certain embodiments, a silicone oil comprises a plurality of Liveo360 Medical Fluids such that a fluid with an intermediate viscosity (e.g., a viscosity between one or more available viscosities) is achieved.
[0119] In certain embodiments, an impregnation fluid comprises one or more of the below listed trimethylsiloxy terminated polydimethysiloxanes or substantial equivalents thereof having the properties listed in Table 1 below:
TABLE-US-00001 Viscosity Product Temp. Pourpoint Specific Refractive Code* Viscosity Coefficient C. Gravity Index DMS-T0 .65 .32 68 .761 1.3750 DMS-T01 1.0 .37 85 .818 1.3825 DMS-T01.5 1.5 .46 75 .853 1.3880 DMS-T02 2.0 .48 80 .873 1.3900 DMS-T03 3.0 .51 70 .898 1.3935 DMS-T05 5.0 .54 65 .918 1.3970 DMS-T07 7.0 .55 65 .930 1.3980 DMS-T11 10 .56 65 .935 1.3990 DMS-T12 20 .59 65 .950 1.4000 DMS-T15 50 .59 65 .960 1.4015 DMS-T21 100 .60 65 .966 1.4025 DMS-T22 200 .60 60 .968 1.4030 DMS-T23 350 .60 60 .970 1.4031 DMS-T25 500 .60 55 .971 1.4033 DMS-T31 1,000 .61 50 .971 1.4034 DMS-T35 5,000 .61 48 .973 1.4035 DMS-T41 10,000 .61 48 .974 1.4035 DMS-T41.2 12,500 .61 46 .974 1.4035 DMS-T43 30,000 .61 43 .976 1.4035 DMS-T46 60,000 .61 42 .976 1.4035 DMS-T51 100,000 .61 41 .977 1.4035 DMS-T53 300,000 .61 41 .977 1.4035 DMS-T56 600,000 .61 41 .978 1.4035 DMS-T61 1,000,000 .62 39 .978 1.4035 DMS-T63 2,500,000 .62 38 .978 1.4035 DMS-T72 20,000,000 .62 35 .979 1.4035
is
TABLE-US-00002 Coeff. of Thermal Thermal Conductivity Cal/ Surface Dielectric Dielectric Flashpoint Molecular Product Code* Expansion 10.sup.4 cm .Math. sec. 10.sup.4 C. Tension Constant Strength C. Weight DMS-T00 13.4 2.4 15.9 2.20 300 1 162 DMS-T01 13.4 2.4 17.4 2.30 350 39 237 DMS-T01.5 13.4 2.5 18.0 2.39 350 63 340 DMS-T02 11.7 2.6 18.7 2.45 350 79 410 DMS-T03 11.4 2.7 19.2 2.50 350 100 550 DMS-T05 11.2 2.8 19.7 2.60 375 135 770 DMS-T07 11.0 3.0 19.9 2.65 375 150 950 DMS-T11 10.8 3.2 20.1 2.68 375 163 1,250 DMS-T12 10.7 3.4 20.6 2.72 375 232 2,000 DMS-T15 10.6 3.6 20.8 2.75 400 285 3,780 DMS-T21 9.3 3.7 20.9 2.75 400 315 5,970 DMS-T22 9.3 3.7 21.0 2.75 400 315 9,430 DMS-T23 9.3 3.8 21.1 2.75 400 315 13,650 DMS-T25 9.3 3.8 21.1 2.75 400 315 17,250 DMS-T31 9.3 3.8 21.2 2.75 400 315 28,000 DMS-T35 9.3 3.8 21.3 2.75 400 315 49,350 DMS-T41 9.3 3.8 21.5 2.75 400 315 62,700 DMS-T41.2 9.3 3.8 21.5 2.75 400 315 67,700 DMS-T43 9.3 3.8 21.5 2.75 400 315 91,700 DMS-T46 9.2 3.8 21.5 2.75 400 315 116,500 DMS-T51 9.2 3.8 21.5 2.75 400 321 139,000 DMS-T53 9.2 3.8 21.5 2.75 400 321 204,000 DMS-T56 9.2 3.8 21.6 2.75 400 321 260,000 DMS-T61 9.2 3.8 21.6 2.75 400 321 308,000 DMS-T63 9.2 3.8 21.6 2.75 400 321 423,000 DMS-T72 9.2 3.8 21.6 2.75 400 321 >500,000
[0120] A person of skill in the art would, in light of the teachings in the present disclosure, understand the provided measurements and be able to extrapolate equivalent silicone fluids based on the disclosure.
[0121] As would be understood by a person of skill in the art, the value, viscosity-temperature coefficient (VTC), is a measure of the change of fluid viscosity over the temperature range 38 C. to 99 C. The VTC can be measured using the following equation: VTC=1(viscosity at 99 C./viscosity at 38 C.).
Thus, the lower the V.T.C. the less the change in viscosity over the temperature range.
[0122] In certain embodiments, an impregnation fluid is or comprises a silicone fluid. A table of silicone fluid classes and associated physical and chemical properties are presented below in Table 2:
TABLE-US-00003 TABLE 2 List of exemplary silicone fluid classes. Organic Thermal Compatible Comment Conventional Silicone Silicone Property on Property Silicone Fluids Fluids Fluids Thermal High Temp C. 1000 hours 175 C. 260 C. 150 C. Properties in air, max. High Temp C. indefinite O.sub.2 200 C. 280 C. free, max. Low Temp C. pour point, 70 C. 73 50 low value Rheological Viscosity, cSt. range 3-2.5 10.sup.6 50-3.0 10.sup.5 500-1 10.sup.4 Properties Visc.-temp. coeff. low value 0.51 0.61 0.75 Electrical Dielectric range 360-400 400-420 Properties Strength volts/mil Dielectric range, 2.50-2.77 2.78-2.95 2.5-3.0 Constant 100 Hz Mechanical Compressibility, @ 20,000 9.1 5.5 approx. 5-8 Properties % psi Density, g/cc 0.90-0.98 0.98-1.15 0.88-1.04 Compatibility Water solubility insoluble insoluble insoluble- Properties partial Hydrocarbon aromatic/ soluble/partial soluble/ soluble/ solubility aliphatic soluble soluble Optical Refractive Index n.sub.d.sup.25 range 1.393-1.403 1.428-1.582 1.443-1.493 Properties Release & Surface Tension, range 19.2-21.6 20.5-28.5 22.0-39.5 Wettability dynes/cm Properties Wear/Lubricity Four ball wear, 2-3 1.8-2.5 0.7 Properties mm at 75 C., 40 kg. load steel on steel, one hr. Hydrophilic and Low Fluorosilicone Polar Silicone Temperature Property Fluids Fluids Silicone Fluids Thermal 190 C. 135 C. 235 C. Properties 230 C. 260 C. 47 C. 50 C. 100 C. Rheological 80-1 10.sup.4 20-5,000 4-400 Properties 0.84 0.5 Electrical 175-200 300-400 Properties 6.95-7.35 Mechanical 7.5 approx. 7 11.9 Properties 1.25-1.30 1.00-1.07 0.76-1.09 Compatibility insoluble insoluble- insoluble Properties soluble insoluble/ partial/ soluble/soluble insoluble insoluble Optical 1.336-1.387 1.441-1.454 1.335-1.588 Properties Release & 25.7-28.7 23.6-27.0 15.9-26.7 Wettability Properties Wear/Lubricity 0.8 2-6 0.9-2.5 Properties
[0123] In certain embodiments, an impregnation fluid is a hydrophilic liquid or a hydrophilic ionic liquid (e.g., when the substrate is a hydrogel). In some embodiments, an impregnation fluid is a liquid comprising ammonia, alcohol(s), one or more amides (e.g., urea), or carboxylic acid (e.g., acetic acid). In certain embodiments, a hydrophilic liquid or a hydrophilic ionic liquid is used when altering adhesion and/or adsorption of hydrophilic proteins.
III. Substrates
[0124] A substrate described herein can be or comprise any suitable substrate that can be infused with an impregnation fluid to achieve desired adhesion or other surface properties. In some embodiments, substrates described herein are polymeric substrates. In some embodiments, a polymeric substrate is cross-linked (e.g., cross-linked polydimethylsiloxane (PDMS)). In some embodiments, a substrate is biocompatible (e.g., does not harm biological tissue).
[0125] In certain embodiments, a polymeric substrate is or comprises silicone. In certain embodiments a silicone is polydimethylsiloxane (PDMS).
[0126] In certain embodiments, a substrate is or comprises a hydrogel, poly(acrylic acid), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethylene glycol), polyacrylamide, or a polysaccharide hydrogels or a modified version or equivalent thereof. In certain embodiments, a substrate is or comprises an organogel. In certain embodiments, an organogel is comprised of anthracene, anthracene, anthraquinone or steroid-based molecules.
[0127] In some embodiments, a substrate is or comprises a hydrogel. In some embodiments, a substrate being or comprising a hydrogel is used to coat a part of a device (e.g., a medical device) where there is a high likelihood of unwanted adhesion of proteins. For example, in some embodiments, joints or parts of a device create turbulent flow, which creates a higher likelihood of proteins adhering to the device at or near these locations. Coating the device with a hydrogel as described herein may help to control protein adhesion or adsorption to the device.
[0128] In certain embodiments, the degree of cross-linking of a polymer substrate can be used to control impregnation of the fluid. For example, in certain embodiments, a lower cross-linking density is associated with a higher amount of fluid being allowed to impregnate the substrate.
[0129] By way of non-limiting example, certain materials useful in creating a polymeric substrate include, but are not limited to, natural and synthetic elastomers such as Ethylene Propylene Diene Monomer (EPDM, a terpolymer of ethylene, propylene and a diene component)), natural and synthetic polyisoprenes such as cis-1,4-polyisoprene natural rubber (NR) and trans-1,4-polyisoprene gutta-percha, isoprene rubber, chloroprene rubber (CR), such as polychloroprene, Neoprene, and Baypren, Butyl rubber (copolymer of isobutylene and isoprene), Styrene-butadiene Rubber (copolymer of styrene and butadiene, SBR), Nitrile rubber (copolymer of butadiene and acrylonitrile, NBR), also called Buna N rubbers, Epichlorohydrin rubber (ECO), Polyacrylic rubber (ACM, ABR), Fluoroelastomers (FKM, and FEPM) Viton, Tecnoflon, Fluorel, Aflas and Dai-El, Perfluoroelastomers (FFKM) Tecnoflon PFR, Kalrez, Chemraz, Perlast, Polyether block amides (PEBA), Chlorosulfonated polyethylene (CSM), (Hypalon), Ethylene-vinyl acetate (EVA), Polybutadiene, Polyether Urethane, Perfluorocarbon Rubber, Fluoronated Hydrocarbon (Viton), silicone, fluorosilicone, polyurethane, polydimethylsiloxane, vinyl methyl silicone, and their composite materials where one or more of such exemplary polymers are compounded with other filler materials such as carbon black, titanium oxide, silica, alumina, nanoparticles, and the like.
IV. Infusion of Substrates with Impregnation Fluids
[0130] As described herein, substrates are infused with an impregnation fluid in order to alter adhesion to the substrate. In certain embodiments, an impregnation fluid reduces adhesion and/or adsorption of proteins to the surface of a substrate.
[0131] In order to achieve certain desirable effects, in some embodiments, the surface of a substrate does not have an overlayer or immobilized layer of impregnation fluid.
[0132] Another method for removal of a free overlayer of impregnation fluid is known as overlayer stripping (e.g., as shown in
[0133] In certain embodiments, adhesion and/or adsorption of proteins to the substrate can be increased or reduced depending on an impregnation fluid used or degree of impregnation. In certain embodiments, it is desirable to increase adhesion and/or adsorption of uncharged proteins to the substrate. In certain embodiments, adhesion and/or adsorption of uncharged proteins not involved in an immune response of the subject in which the substrate is increased. Examples of proteins having a more neutral surface charge include, but are not limited to, UDP-glucose 6-dehydrogenase (UGDH), filamin B (FLNB), and Proteasome 20S Subunit Beta 5 (PSMB5)). In certain embodiments, it is desirable to reduce adhesion for proteins involved in an immune response and/or responsible for adhesion of bacteria to the substrate. Examples of proteins that are responsible for adhesion of bacteria to the substrate include, but are not limited to, fibrinogen and serum albumin.
[0134] Without wishing to be bound to any particular theory, infusion of silicone oil into a polymeric substrate (e.g., PDMS) may result in free silicone oil chains diffusing through the polymeric substrate to places within the bulk (e.g., the polymer bulk) and on the surface of the polymeric substrate which possess a localized charge (e.g., a positive or negative charge). Once at the charge location, the silicone oil neutralizes the localized charges, resulting in altered adhesion properties as compared to untreated substrates.
[0135] In certain embodiments, adhesion or absorption of proteins to a surface of a silicone (e.g., PDMS) substrate is reduced when impregnated with a sufficient amount of silicone oil. In certain embodiments, the adhesion or adsorption of proteins involved in an immune response or responsible for adhesion of pathogens (e.g., bacteria) to a surface is reduced (e.g., as compared to an untreated substrate). Proteins for which adhesion is reduced upon impregnation of a silicone substrate with silicone oil includes fibrinogen and serum albumin. In certain embodiments, adhesion or absorption of proteins to a surface of a silicone substrate is increased when impregnated with a sufficient amount of silicone oil. For example, proteins that are not involved in an immune response of a subject can be increased when the substrate is infused with silicone oil. Exemplary proteins for which adhesion is increased upon impregnation of a PDMS substrate with silicone oil includes UDP-glucose 6-dehydrogenase (UGDH), filamin B (FLNB), and Proteasome 20S Subunit Beta 5 (PSMB5).
IV. Medical Devices
[0136] In certain embodiments, substrates described herein are used with or form all or a part of a medical device. The substrates described herein can be used in any suitable medical device which would benefit from altered surface adhesion properties. In certain embodiments, the medical device is an indwelling medical device. Indwelling medical devices include, but are not limited to, urinary catheters, vascular access devices, endotracheal tubes, tracheostomies, feeding tubes (e.g., enteral feeding tubes), wound drains, and the like. In certain embodiments, medical devices include implantable medical devices (e.g., a device which is either wholly or partially inserted, e.g., surgically, into the body). In certain embodiments, medical devices described herein which comprise the substrate are biocompatible or have portions thereof which are biocompatible (e.g., portions including the medical device). In certain embodiments, medical devices used with methods and substrates described herein are pre-fabricated urinary catheters which are amenable to modification using the techniques described herein.
[0137] In certain embodiments, a medical device is or comprises a tube having an inner surface (i.e., interior) and an outer surface (i.e., exterior). In certain embodiments, a substrate is found on the inner surface of the tube (e.g., a portion in contact with a bodily fluid). In certain embodiments, a substrate is found on the outer surface of the tube (e.g., a portion in contact with a bodily fluid and/or tissue). In certain embodiments, a substrate forms both the inner and outer surfaces of the tube (e.g., as in a catheter). In certain embodiments, a substrate contacts biological tissue and/or biological fluids. Biological fluids include, but are not limited to, urine, blood, interstitial fluids, saliva, intraperitoneal fluids (e.g., abdominal fluids, ascites), gastric juices, and the like.
[0138] In certain embodiments, a medical device or portion thereof comprising the polymeric substrate has reduced adhesion for pathogens (e.g., bacteria) to the medical device. Reduced adhesion of pathogens to the substrate is a result of infusing the substrate with a suitable impregnation fluid as described herein. Pathogens include, but are not limited to, uropathogens such as E. faecalis, C. albicans, uropathogenic Escherichia coli, Pseudomonas aeruginosa, A. baumannii, and Klebsiella pneumoniae.
VI. Experimental Example 1
[0139] In an embodiment discussed herein, host-protein deposition was reduced using liquid-infused (e.g., oil-infused, silicone-oil impregnated) catheters resulting in decreased colonization of bacteria on catheters, in bladders, and dissemination in vivo. Furthermore, proteomics revealed a significant decrease in deposition of host-secreted proteins on liquid-infused catheter surfaces. Findings presented herein suggest targeting microbial binding scaffolds may be an effective, antibiotic-sparing intervention for use against catheter-associated urinary tract infections and other medical device infections.
[0140] Reducing availability of binding scaffolds, in this case fibrinogen (Fg), decreases microbial colonization in a catheterized bladder. A mouse model of CAUTI using a diverse panel of uropathogens, including E. faecalis, C. albicans, uropathogenic Escherichia coli, Pseudomonas aeruginosa, A. baumannii, and Klebsiella pneumonia, found all uropathogens bound more extensively to catheters with Fg present.
[0141] Anti-fouling modifications of the catheter were used to inhibit the deposition of fibrinogen (Fg). In the current embodiment, the anti-fouling modification is liquid infused silicone (LIS) (i.e., silicone infused with a silicone oil). LIS is simpler to make, more stable and more cost effective than other anti-fouling polymer modifications. Additionally, LIS reduces clotting in central lines and infection in skin implants. As disclosed herein, LIS-catheters reduced Fg deposition and microbial binding not only in vitro but also in vivo. Furthermore, LIS-catheters significantly decrease host-protein deposition when compared to unmodified (UM)-catheters as well as reducing catheter-induced inflammation. Without wishing to be bound to any particular theory, the findings presented herein suggest that targeting host-protein deposition on catheter surfaces and the use of LIS-catheters are plausible strategies for reducing instances of CAUTI.
Uropathogens Interact with Fg During CA UTI.
[0142] Due to the interaction between Fg and some uropathogens as well as Fg accumulation on catheters over time in humans and mice, potential interactions of E. faecalis OG1RF (positive control) uropathogenic E. coli UTI89, P. aeruginosa PAO1, K. pneumoniae TOP52, A. baumannii UPAB1, and C. albicans SC5314 with Fg were assessed in vivo, using a CAUTI mouse model. Mice catheterized and infected with the respective uropathogen were sacrificed at 24 hours post infection (hpi). Catheters and bladders were harvested, stained, and imaged. Visual and quantitative analysis of the catheters showed uropathogens co-localizing strongly with Fg deposits, which demonstrates a preference of uropathogens for Fg.
[0143]
[0144]
[0145]
Fg on Urinary Catheter Material Enhances Microbial Binding.
[0146] Based on in vivo findings, it was assessed whether Fg could promote initial binding of the uropathogens to silicone catheters. In addition to Fg, bovine serum albumin (BSA) was tested since serum albumin is one of the most abundant protein on human and mouse urinary catheters as shown in Table 3. Table 3 is a list of proteins found on LI and UM mouse catheters infected with E. faecalis OG1RF. The average number of peptides for each protein found on 10 mouse catheters sorted by greatest abundance on the UM catheter. Table 3 is also found in Andresen et al. Inhibiting host-protein deposition on urinary catheters reduces associated urinary tract infections. eLife 2022; 11:e75798. DOI: doi.org/10.7554/eLife.75798, which is incorporated by reference in its entirety.
TABLE-US-00004 TABLE 3 List of proteins found on LI and UM mouse catheters infected with E. faecalis OG1RF. Decrease UM LI in Catheter Catheter Binding Protein IDs Protein names Average StDev Average StDev (%) P01027 Complement C3 30.50 3.70 10.80 5.55 64.59 H3BKW9 H3BL60 CON_Q2UVX4 P07724 Serum albumin 30.38 3.02 15.80 2.82 47.98 Q921I1 Serotransferrin 25.38 4.34 9.10 2.28 64.14 D3YYR8 F7BAE9 E9Q2Q7 F7CJN9 E9Q939 CON_Q29443 CON_Q0IIK2 CON_Q2HJF0 E9PV24 Fibrinogen alpha, 22.00 8.98 8.70 4.31 60.45 CON_P02672 beta and gamma Q8K0E8 Q3UER8 Q8VCM7 Q8VDD5 Myosin-9 18.86 15.02 6.70 6.57 64.47 Q5SV64 Q3UH59 Q61879 A0A2R8VKI5 Q8BXF2 A0A140LI60 E9Q264 A2AQP0 Q00623 Apolipoprotein 15.00 2.07 6.50 1.35 56.67 A0A1L1STX7 A-I CON_P15497 Q61838 Alpha-2- 13.88 4.76 3.33 2.40 75.98 D3YUI3 macroglobulin Q6GQT1 P20152 Vimentin 11.00 9.77 3.25 3.37 70.45 A0A0A6YWC8 A2AKJ2 P31001 D3YZ35 A0A0R4J036 P46660 P08551 P08553 P11679 Keratin, type II 10.75 1.49 9.10 4.41 15.35 CON_Q9H552 cytoskeletal 8 Q91X72 Hemopexin 10.50 1.93 4.30 2.45 59.05 A0A1B0GS57 B7FAV1 Filamin-A 10.29 9.78 1.00 1.69 90.28 B7FAU9 Q8BTM8 F6XC15 Q8VHX6 F6Z2C0 J3JS91 A8DUK4 Hemoglobin 10.00 3.46 5.90 2.28 41.00 P02088 subunit beta-1 E9Q223 P02089 CON_Q3SX09 CON_P02070 P02104 P13020 Gelsolin 9.88 1.55 4.90 2.81 50.38 A0A0J9YUQ8 CON_Q3SX14 A6PWS5 A0A0J9YUJ8 P20918 Plasminogen 9.38 3.62 1.70 1.83 81.87 CON_P06868 P63260 Actin, 9.25 3.54 6.00 1.63 35.14 P60710 cytoplasmic 2 E9Q5F4 G3UZ07 E9Q1F2 G3UYG0 E9Q606 A0A1D5RM20 B1ATY1 Q8BFZ3 F8WGM8 E9Q2D1 F6WX90 V9GXQ2 B7ZNJ1 Fibronectin 8.88 5.25 1.33 1.73 84.98 A0A087WS56 Anastellin B9EHT6 A0A087WSN6 Q3UHL6 A0A087WR50 P11276 Q4KL80 A0A087WSU6 A0A087WS99 P28665 Murinoglobulin-1 8.50 3.12 1.22 0.97 85.62 P28666 A0A0N4SVU1 CON_ENSEMB L:ENSBTAP0000 0024146 A2BIN1 Major urinary 8.50 3.02 6.40 1.35 24.71 Q4FZE8 protein 6 A2AKN9 A2BIM8 P02762 P04938 A9C497 A9C496 A2CEK7 7.88 3.56 5.70 1.57 27.62 P08071 Lactotransferrin 7.88 7.77 2.70 3.65 65.71 A0A0G2JDN0 A0A0G2JGN1 A0A0G2JFM6 A0A0G2JEA3 P11589 Major urinary 7.88 3.44 5.60 1.51 28.89 protein 2 A2AE89 Glutathione S- 7.63 1.60 7.00 4.40 8.20 P10649 transferase Mu 1 F6WHQ7 P19639 D3YVP6 E9QAC8 D3YVP5 Q80W21 F6Y363 D3YZ29 D3YVP8 G5E8M7 O35660 D3YVP9 E9PV63 E9PVM7 P48774 Q61233 Plastin-2 7.50 7.37 1.33 1.87 82.22 A0A1C7CYV0 B1AX58 Q99K51 D3YZ25 D3YVW8 D3Z7D9 D3Z311 Q3V0K9 G3X9T8 Ceruloplasmin 7.50 2.45 0.50 0.53 93.33 G3X8Q5 E9PZD8 Q61147 G3UXG1 G3UWP5 G3UZ53 A2AKN8 7.50 3.51 5.50 1.27 26.67 E9PVW0 B8JI96 A2BIN0 P11591 P01132 Pro-epidermal 7.38 7.58 2.89 1.83 60.83 A0A0G2JDT8 growth factor A0A0G2JF92 A0A0G2JFB8 P26041 Moesin 7.29 7.70 0.20 0.42 97.25 Q7TSG6 P10107 Annexin A1 7.25 7.38 1.78 2.11 75.48 A0A494BBD8 P40142 Transketolase 7.25 4.68 2.44 1.74 66.28 A0A286YE28 E0CY51 P21614 Vitamin D- 7.25 1.67 2.56 0.73 64.75 A0A0G2JGM6 binding protein A9R9W0 Major urinary 7.00 3.38 5.30 2.06 24.29 A2CEL1 protein 1 P11588 A2CEL0 L7MUC7 A2CEK9 P26039 Talin-1 6.88 7.94 1.70 2.45 75.27 A2AIM2 E9PUM4 A0AILISQ51 Q8CDM9 Q71LX4 F6SX70 A0A1L1SRI1 F6S1V7 A0A1L1SQP9 P68134 Actin, alpha 6.88 3.09 4.30 1.83 37.45 P68033 skeletal muscle P62806 Histone H4 6.63 3.78 4.50 1.84 32.08 P62737 Actin, aortic 6.50 2.88 4.30 1.83 33.85 P63268 smooth muscle A0A494B9T3 D3YZY0 D3Z2K3 A0A0U1RQ96 A0A0R4J0I1 Serine protease 6.38 2.83 1.80 0.92 71.76 P07759 inhibitor A3K Q80X76 A0A2K6EDJ7 Inter alpha- 6.25 1.58 2.30 1.89 63.20 E9Q5L2 trypsin inhibitor, E9PVD2 heavy chain 4 A6X935 CON_Q3T052 A0A0R4J0X5 Alpha-1- 6.25 1.16 3.80 0.79 39.20 A0A0A0MQA3 antitrypsin 1-3 Q00896 P07758 Q00897 Alpha-1- 6.25 0.89 3.90 0.99 37.60 antitrypsin 1-4 Q91VB8 Hemoglobin 6.13 3.27 3.20 2.44 47.76 P01942 subunit alpha P11247 Myeloperoxidase 6.13 6.10 1.50 2.32 75.51 F7DC05 F8WGZ9 A0A0A0MQL9 P10126 Elongation factor 6.13 2.70 4.40 3.06 28.16 D3Z318 1-alpha 1 D3YZ68 P62631 P22599 Alpha-1- 6.13 1.73 2.70 0.67 55.92 antitrypsin 1-2 Q504P4 Heat shock 5.75 4.13 3.13 2.03 45.65 P63017 cognate 71 kDa D3Z5E2 protein E9Q8I0 Complement 5.75 1.04 1.22 1.20 78.74 P06909 factor H D6RGQ0 E9Q8H9 A0A0A6YWP4 A0A0A6YVP8 A2CEK6 Major urinary 5.75 2.92 3.60 1.07 37.39 B5X0G2 protein 17 L7N222 P58252 Elongation factor 5.63 2.88 5.00 4.58 11.11 G3UXK8 2 G3UZ34 A2AH85 O08810 Q9JKF1 Ras GTPase- 5.50 6.35 0.44 0.73 91.92 A0A0UIRNG5 activating-like Q3UQ44 protein IQGAP1 A0A0U1RPU3 Q3UQP1 F8VQ29 Q9D154 Leukocyte 5.38 5.50 1.22 1.99 77.26 Z4YK03 elastase inhibitor Q8VHP7 A Q5SV42 E9Q1Z0 5.38 1.41 3.10 1.29 42.33 P52480 Pyruvate kinase 5.25 3.85 3.80 2.49 27.62 A0A1L1SU37 PKM A0A1L1SQV8 A0A1L1SUV0 A0A1L1SSN6 A0A1L1STV8 A0A1L1ST52 A0A1L1SVH2 E9Q509 G3X925 P53657 P23953 Carboxylesterase 5.25 1.04 2.00 0.82 61.90 D3Z5G7 1C A0A1D5RM42 Q8VCT4 E9PYP1 Q8VCC2 P32261 Antithrombin-III 5.13 2.42 1.70 0.48 66.83 A0A0A6YWH7 CON_P41361 A0A0A6YXS8 A0A0A6YX49 A0A0A6YX70 P06728 Apolipoprotein 5.13 1.64 1.60 0.97 68.78 A-IV P01029 Complement C4-B 5.13 2.42 0.00 0.00 100.00 P15864 Histone H1.2 5.13 2.17 4.20 3.43 18.05 P43277 Histone H1.3 I7HFT9 Q07133 Q91X17 Uromodulin 5.00 3.42 5.00 2.06 0.00 A0A140LI10 P31725 Protein S100-A9 5.00 2.93 3.10 2.18 38.00 P17182 Alpha-enolase 5.00 3.41 1.67 1.87 66.67 Q6PHC1 B1ARR7 B0QZL1 A0A0N4SUI6 B1ARR6 Q5SX61 Q5SX60 D3YVD3 D3Z2S4 J3QPZ9 Q5SX59 D3Z6E4 A0A0N4SUX5 P17183 Q61646 Haptoglobin 5.00 2.14 2.33 2.12 53.33 P08226 Apolipoprotein E 4.88 2.23 1.33 0.50 72.65 A0A1B0GX15 G3UWN5 G3UZM8 D3YTY9 Kininogen-1 4.88 1.36 1.38 1.19 71.79 A0A0R4J038 O08677 D3Z2B2 P05064 Fructose- 4.75 2.19 2.67 2.12 43.86 A6ZI44 bisphosphate Q9CPQ9 aldolase A A6ZI46 D3Z510 A0A0U1RPN8 D3YWI1 D3YV98 A0A0U1RPT5 A6ZI47 P07356 Annexin A2 4.75 4.06 1.78 0.83 62.57 B0V2N8 B0V2N7 B0V2N5 P49290 Eosinophil 4.75 5.57 0.00 0.00 100.00 peroxidase O89053 Coronin-1A 4.75 4.40 1.00 1.80 78.95 G3UYK8 A0A0U1RPY8 D3YW57 G3UX53 D3YXM2 O35744 Chitinase-like 4.71 4.19 1.30 1.83 72.42 F6RU51 protein 3 Q06890 Clusterin 4.63 1.19 2.30 1.42 50.27 E9PUU2 E9PXG5 E9Q8Y5 E9Q9B8 E9Q2G2 Q8CBB6 Histone H2B 4.63 1.85 3.60 1.78 22.16 Q8CGP2 Q8CGP1 Q6ZWY9 Q64525 Q64478 Q64475 P10854 P10853 P70696 Q9D2U9 Q8CGP0 Q64524 P99024 Tubulin beta-5 4.63 3.34 2.20 1.93 52.43 Q9CWF2 chain Q7TMM9 P68372 Q9D6F9 Q922F4 Q9ERD7 CON_ENSEMB L:ENSBTAP0000 O025008 A2AQ07 G3UZR1 A0A1D5RM76 P45376 Aldose reductase 4.63 1.69 4.50 2.92 2.70 D3YVJ7 P06745 Glucose-6- 4.57 4.28 1.50 2.12 67.19 A0A0UIRQ72 phosphate A0A0UIRP97 isomerase CON_Q3ZBD7 A0A0UIRQ18 O08692 Neutrophilic 4.38 2.39 2.20 1.62 49.71 granule protein O35639 Annexin A3 4.33 3.20 1.56 1.67 64.10 Q3TET3 A0A0G2JDV9 A0A0G2JGL7 Q9ET01 Glycogen 4.25 5.26 0.75 1.04 82.35 Q3UEJ6 phosphorylase, E9PUM3 liver form Alpha-1,4 glucan phosphorylase P43274 Histone H1.4 4.25 2.25 3.10 2.28 27.06 P11499 Heat shock 4.14 2.27 2.60 3.20 37.24 E9PX27 protein HSP 90- E9Q3D6 beta D3Z1R1 E9Q0C3 A2A513 Keratin, type I 4.13 2.64 1.80 0.92 56.36 CON_P02535-1 cytoskeletal 10 P02535 A0A0R4J039 Histidine-rich 4.00 1.77 1.22 0.97 69.44 Q9ESB3 glycoprotein A0A338P6H8 D3Z6F5 ATP synthase 3.88 2.75 2.78 2.05 28.32 Q03265 subunit alpha Q831A3 S4R1W1 Glyceraldehyde- 3.88 1.96 2.33 1.41 39.78 P16858 3-phosphate A0A1D5RLD8 dehydrogenase A0A0A0MQF6 S4R257 S4R1W8 V9GX06 A0A0R4J0X7 S4R2G5 Q64467 S4RIN5 V9GXK0 A0A1B0GSR9 L-lactate 3.88 1.81 2.30 1.16 40.65 A0A1B0GSX0 dehydrogenase A P06151 chain A0A1B0GSL7 A0A1B0GT41 A0A1B0GQX5 D3YZQ9 A0A1B0GRW9 A0A1B0GS79 A0A1B0GRC1 A0A1B0GRS2 A0A1B0GSR2 D3YVR7 D3YZE4 A0A1B0GRE9 P00342 B8JJM5 Complement 3.88 1.64 0.56 0.53 85.66 F6VQX8 factor B B8JJN0 P04186 F6XQ00 B8JJM6 H3BK95 B8JJM3 F6W2T4 P63101 14-3-3 protein 3.88 2.59 3.90 2.69 0.65 A0A2I3BQ03 zeta/delta D3YXN6 D3YXF4 D3YW45 P26040 Ezrin 3.86 3.80 2.00 2.79 48.15 Q62266 Cornifin-A 3.75 1.98 4.30 2.50 14.67 Q62267 P68373 Tubulin alpha-1C 3.75 1.39 2.78 2.05 25.93 P05213 chain A0A2R8VHF3 Q9JJZ2 Q3UX10 P24527 Leukotriene A-4 3.75 3.81 0.80 1.14 78.67 hydrolase P19221 Prothrombin 3.75 2.25 1.00 1.22 73.33 H7BX99 CON_P00735 P04104 Keratin, type II 3.75 2.76 2.00 1.00 46.67 cytoskeletal 1 Q00898 Alpha-1- 3.75 1.16 1.80 0.63 52.00 antitrypsin 1-5 O70456 14-3-3 protein 3.71 1.70 5.10 2.56 37.31 sigma A0A0N4SV66 Histone H2A 3.71 1.70 2.00 1.00 46.15 Q8CGP4 C0HKE9 C0HKE8 C0HKE7 C0HKE6 C0HKE5 C0HKE4 C0HKE3 C0HKE2 C0HKE1 Q8CGP6 Q8R1M2 Q8CGP7 Q8CGP5 Q8BFU2 Q64523 Q6GSS7 P27661 Q64522 G3UWL7 P07901 Heat shock 3.71 2.43 1.20 1.32 67.69 B7ZC50 protein HSP 90- A2A6A2 alpha B7ZC49 REV_Q8BL66 A0A0G2JEU1 Aldehyde 3.63 3.74 0.30 0.67 91.72 P47738 dehydrogenase, A0A0G2JF60 mitochondrial A0A0G2JFQ0 D3YYF3 Q62148 G3UWP3 P24549 Q9JHW9 Q9CZS1 A0A1W2P768 Histone H3.2 3.63 2.39 1.70 1.34 53.10 P84228 P68433 F8WI35 P84244 P02301 E0CZ27 E0CYN1 E0CYR7 P07309 Transthyretin 3.63 0.52 1.80 0.79 50.34 P68369 Tubulin alpha-1A 3.63 1.30 2.56 1.67 29.50 P05214 chain O88342 WD repeat- 3.50 3.66 2.10 1.91 40.00 A0A0J9YU05 containing protein 1 Q3UV17 Keratin, type II 3.50 1.07 2.30 0.82 34.29 CON_Q7RTS7 cytoskeletal 2 CON_Q32MB2 oral O88569 Heterogeneous 3.43 4.20 0.67 0.71 80.56 A0A0N4SUM2 nuclear ribonucleoproteins A2/B1 A1BN54 Alpha-actinin-1 3.38 5.15 0.00 0.00 100.00 Q7TPR4 P17751 Triosephosphate 3.38 2.39 2.00 1.50 40.74 H7BXC3 isomerase Q00612 Glucose-6- 3.38 3.42 1.00 1.25 70.37 A3KG36 phosphate 1- Q836V0 dehydrogenase X G3UWD6 REV_P46662 P97324 Q9DCD0 6-phosphogluconate 3.38 2.92 1.56 1.74 53.91 dehydrogenase, decarboxylating Q03734 Serine protease 3.38 1.60 1.00 0.71 70.37 P29621 inhibitor A3M O88844 Isocitrate 3.33 1.75 2.90 2.18 13.00 A0A087WPT4 dehydrogenase A0A087WRS9 [NADP] D3YVY3 cytoplasmic A0A087WRM4 A0A0UIRP68 D6RIL6 P54071 P27773 Protein disulfide- 3.33 2.42 1.00 1.00 70.00 F6Q404 isomerase A3 A0A1B0GR11 Transaldolase 3.29 2.87 0.78 0.97 76.33 Q93092 F8WGL3 Cofilin-1 3.29 1.98 1.33 0.50 59.42 P18760 A0A494B9A7 Q3THW5 Histone H2A.V 3.29 1.50 1.44 0.53 56.04 P0C0S6 Q8R029 Q3UA95 Q542I8 Integrin beta 3.25 3.01 0.90 1.91 72.31 P11835 M0QWA7 D3YYP8 D3Z1S4 P29788 Vitronectin 3.25 1.49 1.00 1.12 69.23 Q3UP87 Neutrophil 3.14 2.48 0.90 1.20 71.36 elastase Q9CQV8 14-3-3 protein 3.14 1.35 2.00 1.41 36.36 A2A5N1 beta/alpha E9Q604 Integrin alpha-M 3.13 4.52 0.11 0.33 96.44 G5E8F1 E9Q5K8 Q3U1U4 P05555 A0A0R4J1B4 P29699 Alpha-2-HS- 3.13 1.73 0.67 0.71 78.67 A0A338P703 glycoprotein A0A338P7G1 A0A338P7H5 A0A338P692 A0A338P6Y6 CON_P12763 P08752 Guanine 3.13 3.36 0.33 0.50 89.33 A0A0A6YWA9 nucleotide- B2RSH2 binding protein A2AE32 G(i) subunit P20612 alpha-2 P18872 Q3V3I2 P50149 A2A610 A2AE31 Q8C040 D3Z2M7 Q8BHK8 F6QPU5 Z4YKV1 Q66L47 Q8CGK7 P63094 Q6R0H7 P24472 Glutathione S- 3.13 0.83 4.70 1.70 50.40 A0A1L1SS61 transferase A4 P97872 Dimethylaniline 3.00 1.85 4.22 3.03 40.74 Q14DT3 monooxygenase Q8C116 [N-oxide- forming] 5 Q01339 Beta-2- 3.00 1.41 0.25 0.46 91.67 I7HJR3 glycoprotein 1 CON_P17690 P04117 Fatty acid- 3.00 1.41 3.22 1.72 7.41 A0A0A6YW05 binding protein, A0A0A6YXB9 adipocyte A0A0A6YXI2 P24526 O08716 Q9CVB6 Actin-related 3.00 2.78 1.00 0.82 66.67 D3YXG6 protein 2/3 A0A087WRT2 complex subunit 2 Q05144 Ras-related C3 3.00 1.69 1.00 1.00 66.67 A0A2R8VHH0 botulinum toxin substrate 2 D3Z6I8 Tropomyosin 3.00 3.34 0.25 0.46 91.67 E9Q7Q3 alpha-3 chain A0A0R4J1P2 P21107 D3YVR0 A2AIM5 S4R2U0 G5E8R0 E9Q453 G5E8R2 G5E8R1 E9Q456 E9Q455 E9Q452 Q8BSH3 Q8BP43 E9Q450 E9Q448 CON_Q3SX28 B7ZNL3 A2AIM4 E9Q454 F8WID5 P58774 P58771 E9Q3Z4 Hexokinase 2.88 4.22 0.11 0.33 96.14 Q3TRM8 E9Q8S8 D6RFA3 P52792 P09411 Phosphoglycerate 2.88 3.72 0.67 0.71 76.81 S4R2M7 kinase 1 P09041 D3Z2H9 2.88 3.27 0.11 0.33 96.14 E9Q5J9 A0A0A0MQA5 Tubulin alpha-4A 2.88 2.64 1.70 1.95 40.87 P68368 chain A0A087WQS4 A0A087WRB4 A0A087WSB0 A0A087WSL5 P51881 ADP/ATP 2.86 1.77 1.00 0.94 65.00 P48962 translocase 2 Q3V132 A0A2R8VHF9 Myosin-11 2.83 2.23 0.67 0.71 76.47 E9QPE7 A0A338P6K2 O08638 Q5SXR6 Clathrin heavy 2.75 4.03 0.44 0.73 83.84 Q68FD5 chain F6Z1R4 Q61598 Rab GDP 2.75 3.06 1.00 1.41 63.64 A0A1Y7VL99 dissociation A0A1Y7VLG4 inhibitor beta P08113 Endoplasmin 2.75 3.20 0.80 1.14 70.91 F7C312 Q8C253 Galectin 2.75 1.98 0.78 0.83 71.72 P16110 P43276 Histone H1.5 2.75 1.39 1.10 1.10 60.00 H3BJQ7 Peroxiredoxin-5, 2.71 1.50 1.50 0.53 44.74 P99029 mitochondrial A0A494BAZ4 G3UZJ4 P40124 Adenylyl 2.63 2.72 1.78 1.09 32.28 B1ARS0 cyclase- D3YTR7 associated protein A0A286YCS6 1 Q9CYT6 P56480 ATP synthase 2.63 1.92 1.50 2.12 42.86 Q831A5 subunit beta, mitochondrial P48036 Annexin A5 2.63 2.33 0.88 0.64 66.67 A0A0G2JGQ0 Q99JI6 Ras-related 2.57 2.57 0.80 1.23 68.89 A0A0G2JDL9 protein Rap-1b P62835 A0A0G2JE52 A0A0G2JED9 A0A1W2P777 P62962 Profilin-1 2.57 2.37 0.78 0.83 69.75 Q5SX49 CON_P02584 Q9R0P5 Destrin 2.50 1.41 1.56 1.33 37.78 P45591 P15947 Kallikrein-1 2.50 2.62 1.90 0.99 24.00 A0A0U1RPN5 P15945 P00757 Q61759 P15946 Q5FW60 Major urinary 2.50 2.20 1.00 0.94 60.00 protein 20 P01898 H-2 class I 2.50 1.20 0.00 0.00 100.00 A0A494B9G2 histocompatibility A0A0B4J1G3 antigen, Q10 A0A494B9G8 alpha chain E9PWT4 E9QJR9 P79568 E9PX63 Q8HWB2 A0A494BA33 A0A494BAT0 Q3TH01 O19441 A7VMS6 E9Q0G4 G3UXE9 P01895 P14430 P14428 P14429 P14426 P01900 P03991 P04223 P01901 Q9DBJ1 Phosphoglycerate 2.43 2.15 0.50 0.53 79.41 O70250 mutase 1 A0A075B5P6 Ig mu chain C 2.43 1.90 0.00 0.00 100.00 A0A075B6A0 region P01872 Q01853 Transitional 2.38 2.20 1.60 1.65 32.63 endoplasmic reticulum ATPase Q3KQQ2 Major urinary 2.38 2.07 1.40 1.07 41.05 P04939 protein 3 Q80YX8 P11590 P17156 Heat shock- 2.38 1.60 1.38 0.74 42.11 related 70 kDa protein 2 P20029 78 kDa glucose- 2.29 2.36 0.40 0.84 82.50 regulated protein P08249 Malate 2.29 1.98 1.20 1.14 47.50 A0A0G2JF23 dehydrogenase, A0A0G2JGY4 mitochondrial P43275 Histone H1.1 2.29 1.25 1.22 1.30 46.53 P00920 Carbonic 2.25 2.66 0.75 0.89 66.67 A0A0A6YX78 anhydrase 2 P30681 High mobility 2.25 2.55 0.00 0.00 100.00 A0A1B0GQX9 group protein B2 O89020 Afamin 2.25 1.16 0.00 0.00 100.00 Q6S9I0 2.25 0.71 0.75 0.46 66.67 Q6S9I2 Q6S9I3 A0A338P699 A0A338P7D0 E0CYI5 CON_P01045-1 CON_Q2KJ62 CON_P01044-1 P16125 L-lactate 2.17 0.75 1.78 1.72 17.95 A0A0N4SVV8 dehydrogenase B D3Z7F0 chain P14733 Lamin-B1 2.14 2.48 0.44 0.73 79.26 A0A0R4J0Q5 P21619 B1AXW5 Peroxiredoxin-1 2.14 0.90 2.10 1.20 2.00 B1AXW6 P35700 B1AXW4 B1AZS9 O08807 P04919 Band 3 anion 2.13 3.36 0.80 1.69 62.35 transport protein Q3UDS7 ADP-dependent 2.13 2.47 0.30 0.67 85.88 A0A1L1SSF2 glucokinase Q8VDL4 A0A075B5P3 Ig gamma-2B 2.13 1.13 0.11 0.33 94.77 A0A0A6YVP0 chain C region P01867 P17742 Peptidyl-prolyl 2.13 1.13 1.00 1.22 52.94 A0A1L1SST0 cis-trans V9GXC1 isomerase A V9GX31 P16045 Galectin-1 2.13 0.64 0.00 0.00 100.00 A0A2R8VHP3 2.13 0.99 1.40 0.97 34.12 Q6IFZ8 D3Z6R0 Q64727 Vinculin 2.00 2.20 0.80 1.32 60.00 P42932 T-complex 2.00 2.08 1.22 1.48 38.89 H3BL49 protein 1 subunit H3BJB6 theta H3BKR8 H3BLL1 H3BKG2 Q61129 Complement 2.00 1.60 0.00 0.00 100.00 A0A0G2JF07 factor I P09528 Ferritin heavy 2.00 2.45 0.00 0.00 100.00 A0A494BA92 chain A0A494B9D4 A0A494BAP3 H3BKI8 Heterogeneous 2.00 2.16 0.40 0.52 80.00 A0A286YDM3 nuclear H3BK96 ribonucleoprotein H3BKD0 K B2M1R6 P61979 A0A286YCM2 H3BLL4 A0A286YEC4 A0A286YE41 H3BJ43 H3BJS9 Q8BT23 A0A286YDH1 P20065 Thymosin beta-4 2.00 1.07 1.56 1.24 22.22 Q19LI2 Alpha-1B- 2.00 1.73 0.00 0.00 100.00 glycoprotein Q9QUI0 Transforming 2.00 1.83 0.70 1.06 65.00 A0A0A6YXF6 protein RhoA Q62159 A0A0G2JEP8 H3BL56 A0A0A6YWJ1 Q9CR99 P62746 E9PZF0 Nucleoside 2.00 1.41 0.30 0.67 85.00 Q01768 diphosphate Q5NC79 kinase Q07456 Protein AMBP 2.00 1.31 0.00 0.00 100.00 P16015 Carbonic 2.00 0.93 0.60 0.52 70.00 anhydrase 3 Q9Z1Q5 Chloride 2.00 1.63 0.30 0.67 85.00 intracellular channel protein 1 Q3TLP8 Ras-related C3 2.00 1.20 0.78 0.83 61.11 P63001 botulinum toxin P60764 substrate 1 A2AC13 A0A2R8VH29 A0A1B0GSL4 G3UZM2 D3Z3L1 F2Z463 D3YX61 Q8R527 Q9ER71 O09131 Glutathione S- 1.88 0.64 2.13 1.81 13.33 A0A494BAB1 transferase A0A494B9X6 omega-1 A0A494BAY2 A0A494BB82 Q8K2Q2 F8WIT2 Annexin 1.88 2.90 0.00 0.00 100.00 P14824 P47791 Glutathione 1.88 2.10 0.80 1.14 57.33 reductase, mitochondrial Q8BND5 Sulfhydryl 1.88 1.73 0.00 0.00 100.00 oxidase 1 D3YY36 Inhibitor of 1.88 0.99 0.43 0.53 77.14 Q9DBD0 carbonic F6W4D3 anhydrase E9PWU4 Adiponectin 1.88 0.35 0.11 0.33 94.07 Q60994 P61982 14-3-3 protein 1.88 1.25 1.70 1.42 9.33 gamma Q9DC51 Guanine 1.88 2.03 0.33 0.50 82.22 nucleotide- binding protein G(k) subunit alpha F8WJ05 Inter-alpha- 1.86 0.69 0.00 0.00 100.00 Q61702 trypsin inhibitor heavy chain H1 P08228 Superoxide 1.83 0.75 1.89 1.54 3.03 dismutase [CuZn] Q9Z2U0 Proteasome 1.83 0.98 0.89 1.05 51.52 A0A338P7D7 subunit alpha Q9CWH6 type-7 B7ZMS4 Q8BJS4 SUN domain- 1.75 1.98 0.20 0.42 88.57 containing protein 2 Q5SW88 Ras-related 1.75 1.49 1.13 1.25 35.71 P62821 protein Rab-1A Q5SW87 A0A494BA38 A0A494BBL7 A0A494B945 Q9D1G1 Q5SW86 Q9DBB9 Carboxypeptidase 1.75 0.46 0.00 0.00 100.00 N subunit 2 P51150 Ras-related 1.75 1.91 0.44 0.73 74.60 A0A0N4SVR6 protein Rab-7a A0A0N4SVG9 E9Q1Y9 Keratin, type II 1.75 1.39 0.75 0.46 57.14 CON_Q61726 cuticular Hb1 Q9ERE2 P97861 Q6IMF0 CON_P78386 Q9Z2T6 CON_043790 CON_Q6NT21 CON_P78385 CON_Q14533 A0A0A6YW67 Ubiquitin-60S 1.75 0.89 1.50 0.53 14.29 E9Q9J0 ribosomal protein E9Q4P0 L40 E9Q5F6 E9QNP0 Q5SX22 P62984 P62983 P0CG49 P0CG50 D3YX76 Glutathione S- 1.75 0.46 1.40 0.70 20.00 P15626 transferase Mu 2 P47911 60S ribosomal 1.71 1.98 1.56 1.59 9.26 A0A0J9YU32 protein L6 P08905 Lysozyme C-2 1.71 1.38 0.70 1.06 59.17 P17897 Q9CQI6 Coactosin-like 1.71 1.38 0.50 0.71 70.83 A0A1D5RLP1 protein Q9CZX8 40S ribosomal 1.67 1.03 1.10 0.99 34.00 D3YUT3 protein S19 D3YUG3 D3Z5R8 D3Z722 S4R223 P14069 Protein S100-A6 1.63 0.52 2.00 0.47 23.08 Q8BH61 Coagulation 1.63 2.20 0.00 0.00 100.00 factor XIII A chain P60843 Eukaryotic 1.63 0.92 1.67 1.32 2.56 Q8BTU6 initiation factor P10630 4A-I E9Q561 A0A338P6X5 P48999 Arachidonate 5- 1.63 2.07 0.11 0.33 93.16 E9QA93 lipoxygenase E9Q6H6 A0A0N4SW45 A0A1B0GSG5 Ribonuclease 1.63 1.30 0.90 1.20 44.62 Q91VI7 inhibitor A0A1B0GRG4 S4RIN6 40S ribosomal 1.63 0.92 0.78 0.83 52.14 F6YVP7 protein S18 P62270 A0A1Y7VKY1 A0A3Q4EGP3 Q5ND35 Alpha-2- 1.63 1.41 0.00 0.00 100.00 Q61247 antiplasmin E9PXE0 Q99JY9 Actin-related 1.63 1.77 0.50 0.71 69.23 A0A087WS98 protein 3 A0A087WP86 A0A087WQ14 A0A087WRA1 Q641P0 A0A087WQ83 P97369 Neutrophil 1.63 1.85 0.11 0.33 93.16 A8XU21 cytosol factor 4 Q8BT60 Copine-3 1.63 1.77 0.00 0.00 100.00 Q9D6C8 A0A0R4J0J1 Q3UYN2 Q1RLL3 Q9Z140 Q8BLR2 Q0VE82 Q9DC53 Q8JZW4 P09405 Nucleolin 1.57 1.72 1.20 1.40 23.64 Q91YR9 Prostaglandin 1.57 1.27 0.60 0.84 61.82 REV_Q3TVC7 reductase 1 REV_A0A0R4J177 P50247 Adenosylhomocy 1.57 0.98 1.00 0.94 36.36 A2ALT5 steinase P05202 Aspartate 1.57 1.27 0.70 1.06 55.45 aminotransferase, mitochondrial P62259 14-3-3 protein 1.57 1.13 1.89 0.93 20.20 F6WA09 epsilon D6REF3 P84096 Rho-related GTP- 1.57 0.79 0.56 0.53 64.65 binding protein RhoG P62908 40S ribosomal 1.50 1.87 1.56 1.74 3.70 D3YV43 protein S3 A0A140LI77 P97384 Annexin A11 1.50 2.00 0.25 0.46 83.33 D3Z7U0 O70145 Neutrophil 1.50 1.93 0.00 0.00 100.00 A0A087WPH0 cytosol factor 2 Q543K9 Purine nucleoside 1.50 1.85 0.33 0.50 77.78 P23492 phosphorylase A0A2I3BQH2 A0A2I3BS22 Q9D8C9 A0A0J9YUZ4 High mobility 1.50 1.69 0.00 0.00 100.00 P63158 group protein B1 A0A0J9YUD8 D3YVC6 D3YZ18 G3X8T9 Serine protease 1.50 0.76 0.78 0.44 48.15 Q91WP6 inhibitor A3N H7BWY0 Q6P4P1 A0A0R4IZY6 Myeloblastin 1.50 1.41 1.00 1.33 33.33 Q61096 F6ZK01 E9PZ00 Prosaposin 1.50 1.07 0.38 0.74 75.00 Q8BFQ1 K3W4L3 J3QPG5 Q61207 P68254 14-3-3 protein 1.50 1.07 1.78 0.83 18.52 theta Q839G8 1.43 1.13 0.40 0.84 72.00 Q9CPX4 Ferritin 1.43 1.40 0.00 0.00 100.00 A0A1B0GR60 P29391 A0A1B0GRH4 P49945 A0A1Y7VNT9 Q9WVA4 Transgelin-2 1.38 2.00 0.44 0.73 67.68 A0A0A6YXG6 Q9R1Q8 Q61599 Rho GDP- 1.38 1.77 0.40 0.52 70.91 D3YWL7 dissociation A0A0N4SVH4 inhibitor 2 Q8VEK3 Heterogeneous 1.38 2.00 0.50 0.71 63.64 nuclear ribonucleoprotein U P09103 Protein disulfide- 1.38 2.00 1.00 1.05 27.27 E9Q8G8 isomerase Q9JM76 Actin-related 1.38 1.60 0.30 0.67 78.18 H7BWZ3 protein 2/3 A0A0G2JFK7 complex subunit D3Z2F7 3 D3Z2F8 P29351 Tyrosine-protein 1.38 1.85 0.11 0.33 91.92 phosphatase non- receptor type 6 P41245 Matrix 1.38 1.60 0.30 0.67 78.18 metalloproteinase- 9 Q91Z25 Actin-related 1.38 1.85 0.11 0.33 91.92 Q9WV32 protein 2/3 F6VVE6 complex subunit D3Z6S0 1B F6THG2 G3UY29 Ras-related 1.38 1.60 0.78 0.83 43.43 E9Q3P9 protein Rab-11A F8WGS1 Ras-related P62492 protein Rab-11B P46638 G3UZD3 G3UZL4 D3YYB3 Q9QZQ8 Core histone 1.38 1.60 0.56 0.53 59.60 Q8CCK0 macro-H2A.1 A6BLY7 Keratin, type I 1.38 0.52 1.33 0.50 3.03 cytoskeletal 28 Q60590 Alpha-1-acid 1.38 1.06 0.00 0.00 100.00 glycoprotein 1 Q3U9G9 Lamin-B receptor 1.38 1.77 0.22 0.67 83.84 A0A0A6YWS3 A0A0A6YXW3 A0A0A6YXT6 A0A0A6YW01 A0A0A6YY12 P62827 GTP-binding 1.38 0.74 0.50 0.53 63.64 Q14AA6 nuclear protein Q61820 Ran P10639 Thioredoxin 1.38 0.74 0.60 0.52 56.36 Q8VCU2 Phosphatidylinosi 1.38 1.06 0.00 0.00 100.00 O70362 tol-glycan- specific phospholipase D A0A0A6YY34 Glutathione 1.38 1.51 0.00 0.00 100.00 A0A0A6YVV2 peroxidase P11352 Glutathione peroxidase 1 P01897 H-2 class I 1.38 1.51 0.00 0.00 100.00 P01899 histocompatibility P01896 antigen, L-D alpha chain Q91Z98 Chitinase-like 1.38 1.51 0.50 0.71 63.64 protein 4 P14211 Calreticulin 1.33 1.21 0.30 0.67 77.50 G3X977 Inter-alpha- Q61703 trypsin inhibitor Q3UEG7 heavy chain H2 CON_Q9TRI1 1.33 0.52 0.11 0.33 91.67 Q61171 Peroxiredoxin-2 1.29 0.49 1.50 1.08 16.67 D3Z4A4 P14152 Malate 1.29 1.11 0.67 0.71 48.15 dehydrogenase, cytoplasmic Q06770 Corticosteroid- 1.29 1.11 0.00 0.00 100.00 binding globulin P28293 Cathepsin G 1.29 1.11 0.11 0.33 91.36 Q3THE2 Myosin 1.29 0.49 0.60 0.52 53.33 Q6ZWQ9 regulatory light Q9CQ19 chain 12B Myosin regulatory light polypeptide 9 Q8CI94 Glycogen 1.25 1.83 1.80 1.87 44.00 phosphorylase, brain form P50516 V-type proton 1.25 1.75 0.00 0.00 100.00 D3Z1B9 ATPase catalytic D3YWH3 subunit A D3YZ23 Q61093 Cytochrome b- 1.25 1.75 0.11 0.33 91.11 E9Q7S3 245 heavy chain E9Q802 P49710 Hematopoietic 1.25 1.75 0.00 0.00 100.00 E9Q4E5 lineage cell- specific protein Q6P069 Sorcin 1.25 1.39 0.30 0.48 76.00 A0A1L1SQA8 40S ribosomal 1.25 0.46 0.89 0.60 28.89 P62852 protein S25 Q9QXC1 Fetuin-B 1.25 0.46 0.11 0.33 91.11 Q6YJU1 P68510 14-3-3 protein eta 1.25 0.89 1.50 1.18 20.00 A2AE91 1.25 0.46 1.30 0.48 4.00 Q8R516 Q80X90 Filamin-B 1.17 1.17 4.00 4.76 242.86 P51885 Lumican 1.17 0.41 0.00 0.00 100.00 CON_Q05443 Q9CZM2 60S ribosomal 1.17 0.41 0.56 0.53 52.38 B8JKK2 protein L15 Ribosomal protein L15 P21550 Beta-enolase 1.17 0.41 0.00 0.00 100.00 G3X9D9 Involucrin 1.14 0.90 2.90 2.42 153.75 P48997 Q3U3V1 Coagulation 1.14 0.90 0.00 0.00 100.00 O88947 factor X A0A1W2P6F6 Myosin light 1.14 0.90 0.11 0.33 90.28 A0A1W2P7Q9 polypeptide 6 Q60605 A0A1W2P6G5 P60766 Cell division 1.14 0.38 0.67 0.71 41.67 control protein 42 homolog P11680 Properdin 1.14 0.38 0.20 0.42 82.50 H7BWY6 Retinol-binding 1.14 0.38 0.11 0.33 90.28 Q00724 protein 4 A0A494B9P3 A0A494B9T2 Q8R2S8 CD177 antigen 1.13 1.36 0.70 1.49 37.78 Q3SXK0 Uroplakin-2 1.13 0.83 1.22 1.20 8.64 P38575 P03953 Complement 1.13 1.36 0.30 0.67 73.33 factor D Q02053 Ubiquitin-like 1.13 1.55 0.56 0.53 50.62 P31254 modifier- activating enzyme 1 Q99LB4 Macrophage- 1.13 1.55 0.67 0.71 40.74 P24452 capping protein D3YZN3 D3YU77 D3YTL5 D3Z4K5 S4R293 Neutrophil 1.13 1.36 0.11 0.33 90.12 F8WH69 cytosol factor 1 Q09014 P06684 Complement C5 1.13 1.25 0.00 0.00 100.00 P14131 40S ribosomal 1.13 1.46 0.33 0.50 70.37 protein S16 P26262 Plasma kallikrein 1.13 0.99 0.00 0.00 100.00 P62918 60S ribosomal 1.13 0.83 1.00 0.94 11.11 protein L8 E9Q499 Serine protease 1.13 0.35 0.78 0.44 30.86 F2Z405 inhibitor A3G Q512A0 Q9R0P9 Ubiquitin 1.00 1.00 1.80 1.32 80.00 carboxyl-terminal hydrolase isozyme L1 O70475 UDP-glucose 6- 1.00 0.76 1.90 0.99 90.00 D3YXP9 dehydrogenase A0A0A6YW77 Neutrophil 1.00 1.20 0.11 0.33 88.89 P11672 gelatinase- associated lipocalin Q61792 LIM and SH3 1.00 1.20 0.33 0.50 66.67 A2A6G9 domain protein 1 A2A6H0 A2A6G7 A2A6G8 A2A6G0 A2A6G6 P70460 Vasodilator- 1.00 1.41 0.30 0.67 70.00 stimulated phosphoprotein D3Z1T4 Guanine 1.00 0.89 0.00 0.00 100.00 D3Z1M1 nucleotide- D3YZX3 binding protein E9QKR0 G(I)/G(S)/G(T) P62880 subunit beta-2 H3BLF7 H3BKR2 P29387 P62874 E9PWM7 Q61011 P84084 ADP-ribosylation 1.00 1.31 0.60 0.84 40.00 factor 5 Q5RKN9 F-actin-capping 1.00 1.31 0.00 0.00 100.00 P47753 protein subunit A0A0G2JE27 alpha-1 P61358 60S ribosomal 1.00 0.76 0.50 0.71 50.00 A2A4Q0 protein L27 A0A0R4J0R1 Vesicle- 1.00 1.20 0.00 0.00 100.00 O70404 associated A0A0U1RPE8 membrane protein 8 P01837 Ig kappa chain C 1.00 0.00 0.00 0.00 100.00 region P01887 Beta-2- 1.00 0.76 1.00 0.00 0.00 microglobulin P30115 Glutathione S- 1.00 0.00 1.50 0.71 50.00 Q6P8Q0 transferase A3 P13745 A0A087WQI6 D3Z6A6 D3YZV3 P10648 P60335 Poly(rC)-binding 1.00 1.07 0.80 0.79 20.00 protein 1 O08997 Copper transport 1.00 0.00 0.00 0.00 100.00 protein ATOX1 A0A0R4J043 Meprin A subunit 1.00 0.76 0.78 0.44 22.22 P28825 alpha I7HPY0 SH3 domain- 1.00 0.00 1.00 0.00 0.00 Q91VW3 binding glutamic acid-rich-like protein 3 Q3UA72 Actin-related 1.00 0.00 0.60 0.52 40.00 Q9CPW4 protein 2/3 complex subunit 5 P61027 Ras-related 1.00 0.00 0.89 0.93 11.11 protein Rab-10 P57096 Prostate stem cell 1.00 0.00 0.33 0.50 66.67 antigen P07361 Alpha-1-acid 1.00 0.82 0.00 0.00 100.00 glycoprotein 2 O09043 Napsin-A 1.00 0.00 0.80 0.42 20.00 P62242 40S ribosomal 0.88 1.36 0.78 0.83 11.11 protein S8 P59999 Actin-related 0.88 0.99 0.33 0.50 61.90 Q3TX55 protein 2/3 E9PWA7 complex subunit 4 G3UX26 Voltage- 0.88 0.99 0.25 0.46 71.43 Q60930 dependent anion- D3YZT5 selective channel A0A286YCR8 protein 2 D3YUN8 Q9Z183 Protein-arginine 0.88 1.13 0.00 0.00 100.00 E9QAM4 deiminase type-4 Q9Z184 Q9CR57 60S ribosomal 0.88 0.64 0.67 0.71 23.81 protein L14 P19783 Cytochrome c 0.88 0.99 0.30 0.67 65.71 oxidase subunit 4 isoform 1, mitochondrial Q62093 Serine/arginine- 0.88 0.99 0.40 0.52 54.29 rich splicing factor 2 P84078 ADP-ribosylation 0.88 1.13 0.40 0.52 54.29 P61205 factor 1 Q8BSL7 D3YV25 E9Q2C2 A2A6T9 E9PZW0 Desmoplakin 0.86 0.69 1.29 1.25 50.00 E9Q557 B1ARA3 60S ribosomal 0.86 1.21 0.67 0.71 22.22 P61255 protein L26 B1ARA5 Q835M3 0.86 0.69 0.11 0.33 87.04 Q8C266 Ras-related 0.86 0.69 0.33 0.50 61.11 Q9CQD1 protein Rab-5A P61021 P35278 A2A5F6 A2A5F5 Q91V55 40S ribosomal 0.83 0.75 0.60 0.84 28.00 D3YYM6 protein S5 D3Z1S8 P97461 H3BK03 Serum 0.83 0.75 0.00 0.00 100.00 P52430 paraoxonase/aryl H3BLB8 esterase 1 A0A075B5P5 Ig gamma-3 0.83 0.75 0.00 0.00 100.00 A0A1Y7VJN6 chain C region P03987 Q61878 Bone marrow 0.75 0.89 0.00 0.00 100.00 proteoglycan Q9D8N0 Elongation factor 0.75 0.71 1.00 1.22 33.33 1-gamma P00329 Alcohol 0.75 0.46 2.00 1.94 166.67 dehydrogenase 1 A0A494BBB0 Calpain-1 0.75 1.39 1.00 1.12 33.33 O35350 catalytic subunit A0A1L1SU53 Twinfilin-2 0.75 0.89 0.00 0.00 100.00 Q9Z0P5 A0A087WRG4 A0A1L1STC8 Q91XL1 0.75 0.89 0.00 0.00 100.00 F7CAZ6 F-actin-capping 0.75 0.89 0.00 0.00 100.00 A2AMW0 protein subunit P47757 beta A0A0A0MQI9 F6YHZ8 Q8CB58 Polypyrimidine 0.75 0.89 0.11 0.33 85.19 Q8BGJ5 tract-binding Q922I7 protein 3 F7C521 F7DCW4 E9QMW9 G8JL74 G3UXA6 Q8BHD7 P17225 A0A075B5P4 Ig gamma-1 0.75 0.46 0.33 0.50 55.56 A0A0A6YWR2 chain C region P01868 secreted form P01869 G3UYV7 40S ribosomal 0.75 0.46 0.56 0.53 25.93 P62858 protein S28 E9PUM5 0.75 0.89 0.20 0.42 73.33 E9Q8B6 E9Q8B5 Q61405 Q3UDR8 Protein YIPF3 0.75 0.46 0.75 0.46 0.00 Protein YIPF3, N-terminally processed P50396 Rab GDP 0.75 0.89 0.88 1.13 16.67 D6RI86 dissociation inhibitor alpha P45377 Aldose reductase- 0.71 0.95 1.50 1.35 110.00 P21300 related protein 2 Aldose reductase- related protein 1 P97351 40S ribosomal 0.71 0.95 0.90 0.88 26.00 protein S3a P62264 40S ribosomal 0.71 0.95 1.25 0.89 75.00 D3YVF4 protein S14 D3Z711 M0QWU8 Acyl-CoA- 0.71 0.49 0.20 0.42 72.00 P31786 binding protein P49182 Heparin cofactor 2 0.71 1.11 0.00 0.00 100.00 B1B1A8 Myosin light 0.71 0.49 0.11 0.33 84.44 Q6PDN3 chain kinase P97315 Cysteine and 0.71 0.49 0.00 0.00 100.00 glycine-rich protein 1 P51437 Cathelin-related 0.71 0.49 0.40 0.52 44.00 antimicrobial peptide P07515 0.71 0.49 0.11 0.33 84.44 E9PUZ8 C4b-binding 0.71 0.49 0.00 0.00 100.00 P08607 protein Q830Q8 0.71 0.49 0.40 0.52 44.00 P06801 NADP-dependent 0.67 0.52 1.63 1.69 143.75 Q3TQP6 malic enzyme Malic enzyme P05366 Serum amyloid 0.67 0.52 0.20 0.42 70.00 A0A1B0GQV5 A-1 protein P05367 Serum amyloid A-2 protein Amyloid protein A D3Z1V4 Phosphatidyletha- 0.67 0.52 0.33 0.50 50.00 P70296 nolamine-binding protein 1 Q76MZ3 Serine/threonine- 0.63 1.19 1.00 1.12 60.00 G3UWL2 protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform P26350 Prothymosin 0.63 0.74 0.44 0.73 28.89 A0A087WP98 alpha A0A087WPN6 Prothymosin A0A087WQN2 alpha, N- terminally processed Thymosin alpha A0A2C9F2D2 Annexin A7 0.63 1.19 0.80 0.92 28.00 Q07076 A0A286YCW4 F6UFG6 Acidic leucine- 0.63 0.74 0.25 0.46 60.00 D3YYE1 rich nuclear D3Z7M9 phosphoprotein O35381 32 family Q9EST5 member A Q64G17 P26443 Glutamate 0.63 0.74 0.70 0.67 12.00 dehydrogenase 1, mitochondrial Q921R2 40S ribosomal 0.63 0.74 0.40 0.52 36.00 P62301 protein S13 A0A0UIRQ71 P97425 Eosinophil 0.63 0.74 0.00 0.00 100.00 cationic protein 2 P27005 Protein S100-A8 0.63 0.74 0.11 0.33 82.22 Q839F8 0.63 0.74 0.00 0.00 100.00 A0A494BA97 Osteoclast- 0.63 0.74 0.00 0.00 100.00 Q62422 stimulating factor 1 A0A494B943 Q6ZWV7 60S ribosomal 0.60 0.55 0.56 0.53 7.41 protein L35 P80314 T-complex 0.57 1.51 1.11 1.27 94.44 A0A1W2P7B7 protein 1 subunit A0A1W2P828 beta A0A1W2P871 A0A1W2P6Q3 Q99PT1 Rho GDP- 0.50 0.53 0.44 0.73 11.11 dissociation inhibitor 1 D3YVG1 Septin-1 0.50 0.53 0.00 0.00 100.00 D3Z3V3 P42209 O08553 Dihydropyrimidinase- 0.50 0.53 0.00 0.00 100.00 related protein 2 Q9D6Y7 Mitochondrial 0.50 0.53 0.11 0.33 77.78 A0A1B0GT40 peptide methionine sulfoxide reductase Q9WTL2 Ras-related 0.50 0.53 0.60 0.84 20.00 protein Rab-25 Q9DCM0 Persulfide 0.50 0.53 0.00 0.00 100.00 dioxygenase ETHE1, mitochondrial P97426 Eosinophil 0.50 0.53 0.00 0.00 100.00 O35290 cationic protein 1 Eosinophil cationic-type ribonuclease 3 P84104 Serine/arginine- 0.50 0.53 0.00 0.00 100.00 rich splicing factor 3 Q60932 Voltage- 0.50 0.53 0.00 0.00 100.00 dependent anion- selective channel protein 1 Q9QXT9 Zinc finger 0.50 0.53 0.00 0.00 100.00 protein 354B P80316 T-complex 0.43 0.53 0.88 0.64 104.17 E0CZA1 protein 1 subunit epsilon P63038 60 kDa heat 0.43 0.53 1.00 0.94 133.33 shock protein, mitochondrial D3Z4N2 Osteopontin 0.43 0.53 0.71 0.49 66.67 F8WIP8 P10923 P97429 Annexin A4 0.38 0.74 1.11 1.17 196.30 F7ANV6 Annexin D3Z0S1 A0A0N4SW89 A0A0N4SV57 S4R1F2 P25444 40S ribosomal 0.38 0.74 0.11 0.33 70.37 D3YVC1 protein S2 D3YWJ3 P60867 40S ribosomal 0.33 0.52 0.78 0.83 133.33 protein S20 A0A0R4J1C2 Calpain small 0.33 0.52 0.60 0.52 80.00 A0A0R4IZW8 subunit 1 O88456 Calpain small Q9D7J7 subunit 2 Q9CX34 Suppressor of G2 0.29 0.76 0.56 0.53 94.44 allele of SKP1 homolog P14115 60S ribosomal 0.25 0.46 0.60 0.52 140.00 protein L27a G3UYI4 26S proteasome 0.14 0.38 0.56 0.53 288.89 G3UYL3 non-ATPase Q8BG32 regulatory subunit 11 O55234 Proteasome 0.00 0.00 0.80 0.79 N/A Q8BTY5 subunit beta type-5 Q921L6 Src substrate 0.00 0.00 1.00 1.22 N/A Q60598 cortactin
[0147] Uropathogen binding to Fg- (Fibrinogen), BSA- (bovine serum albumin), and uncoated silicone (UC) were compared as shown in
[0148]
[0149] Fg significantly enhanced the binding to the catheter for all uropathogens when compared with uncoated and BSA-coated silicone catheters (
Characterization of Liquid-Infused Catheters to Prevent Host-Protein Deposition.
[0150] Based on the exploitative interaction of uropathogens with deposited Fg, a material to prevent protein deposition would also reduce microbial colonization. Liquid-infused surfaces resist protein and bacterial fouling. Inventors developed a LIS material by modifying medical-grade silicone using inert trimethyl-terminated polydimethylsiloxane fluid (referred to as silicone oil in the present example).
[0151]
[0152] Analysis of the silicone oil's infusion rate into silicone tubing showed a significant increase in silicone weight during the first 3 days of infusion then a gradual decrease in infusion until a plateau was reached after about 50 hrs. The change in raw weight is shown in
[0153] Full infusion of mouse silicone catheters was achieved by 10 min as shown in
LIS Modification Reduces Fg Deposition and Microbial Binding In Vitro.
[0154] The ability of the LIS-catheters to reduce Fg deposition in vitro was tested for a silicone-oil impregnated, medical-grade silicone material and two commercially available urinary catheters, Dover and Bardex. Unmodified (UM) versions of each material were used as controls. Each was incubated with Fg overnight and assessed by IF. Fg deposition was reduced in all LIS-catheters, showing 90% decrease on the Dover catheter and 100% on the Bardex catheter and medical-grade silicone tubings when compared with the corresponding unmodified controls (
[0155] Based on LIS's success in reducing Fg deposition, its ability to prevent microbial surface binding was tested. Six uropathogens were grown in urine supplemented with BSA at 37 C. as shown in Table 4 below. In the table, YPD, LB, and BHI are different culture broth tunes used for growth of bacteria
TABLE-US-00005 TABLE 4 List of microbial strains and their corresponding growth conditions, inoculum concentrations and antibodies. Growth Inoculum Primary WT strain Conditions CFU/mL Antibody Reference E. faecalis 24 hr in BHI 1 10{circumflex over ()}7 Rabbit anti- (Flores-Mireles, OG1RF Streptococcus Pinkner, Caparon, group D & Hultgren, 2014) antigen E. coli UTI89 2 24 hr in LB 1 10{circumflex over ()}7 Rabbit anti- (Westfall et al., HK::GFP E. coli Serotype 2019) O/K (ThrmoSci PA1-25636) P. aeruginosa 2 24 hr in LB 1 10{circumflex over ()}7 Rabbit anti- (Berger et al., PA01 PKA Pseudomonas 2014) (ThermoSci PA1-73116) A. baumanii 2 24 hr in LB 1 10{circumflex over ()}8 Rabbit anti- (Di Venanzio et UPAB1 A. baumannii al., 2019) K. pneumoniae 2 24 hr in LB 1 10{circumflex over ()}7 Rabbit anti- (Rosen et al., TOP52 K. pneumoniae 2008) (ThermoSci PA1-7226) C. albicans 24 hr in YPD 1 10{circumflex over ()}7 Rabbit anti- (Baron et al., SC3415 C. albicans 2020) (ThrmoSci PA1-2158)
[0156] Cultures were normalized in urine, added to UM control and LIS-catheters, incubated under static conditions and assessed via IF. Analysis found the LIS-catheters showed significantly reduced binding of all uropathogens when compared to UM controls (
Fg Deposition and Microbial Biofilms on Catheters was Reduced by LIS.
[0157] Mice were catheterized with either an UM- or LIS-catheter and challenged with 210.sup.7 CFU of one of six uropathogens for 24 hrs. Bladders and catheters were harvested and assessed for microbial burden by CFU (colony forming unit) enumeration or fixed for staining. Kidneys, spleens and hearts were collected to determine microbial burden. The results of the study are shown in
[0158] Mice with LIS-catheters had significantly reduced microbial colonization in the bladder and on catheters when compared with UM-catheterized mice regardless of the infecting uropathogen (
[0159] Additionally, colonization was significantly lower in LIS-catheterized mouse kidneys for P. aeruginosa, A. baumannii, and E. coli infections (
[0160] Furthermore, IF imaging and quantification of catheters confirmed decreased Fg deposition and microbial biofilms on LIS-catheters compared to UM (e.g., as shown in
[0161] These data demonstrate pathogens preferentially bind to Fg, and that the LIS-modification successfully reduced Fg deposition. Fg served as the microbes' binding platform. The reduced Fg deposition disrupts uropathogen biofilm formation on catheters and colonization of the bladder in vivo.
[0162]
[0163] Hematoxylin and eosin (H&E) analysis shows the LIS-catheter does not exacerbate bladder inflammation regardless of the presence of infection or not (panels A-F and M of
[0164] Importantly, H&E analysis (
LIS Modification Reduces Protein Deposition on Catheters in CA UTI Mouse Model of E. faecalis.
[0165] A quantitative-proteomics comparison was performed to identify proteins deposited on UM- and LIS-catheters retrieved 24 hpi with E. faecalis. Harvested catheters were prepared and protease digested with trypsin as in Zougman et al. (2014). nLC-MS/MS was performed in technical duplicate and label-free-proteomics (LFQ) processed as in Cox and Mann, 865 proteins were identified at a 1% FDR (Cox & Mann, 2008). The total abundance of protein was significantly reduced in LIS-catheters vs UM-catheters (
LIS-Catheter Reduces Host-Protein Deposition In Vivo
[0166] A subset of UM-catheters and LIS-catheters taken from mice 24 hpi (hours post-infection) with E. faecalis were assessed for protein deposition via mass spectrometry as shown in
Image Montage of Liquid Infused and Unmodified Catheters
[0167]
DISCUSSION
[0168] To the inventors' knowledge, this is the first study to show a diverse set of uropathogens including gram-negative, gram-positive, and fungal species interact with Fg to more effectively bind to silicone urinary catheter surfaces. Furthermore, disrupting Fg deposition with LIS-catheters reduced the ability of uropathogens to bind and colonize the catheter surface and bladder in an in vivo CAUTI mouse model. Moreover, LIS also reduced dissemination of E. coli, P. aeruginosa, and A. baumannii into the kidneys and other organs. Finally, LIS-catheters did not increase inflammation and, for half of the pathogens, inflammation was reduced. Furthermore, the deposition of other host-secreted proteins on LIS-catheters is around 6.5 fold less then UM-catheters. Together, these findings indicate that catheters made using LIS are a promising antibiotic sparing approach for reducing or preventing CAUTIs by interfering with protein deposition.
[0169]
[0170] Pathogen-Fg interaction is important during urinary catheterization for both E. faecalis and S. aureus. Binding to Fg is critical for efficient bladder colonization and biofilm formation on the catheter via protein-protein interaction using EbpA and CHB adhesins, respectively and their disruption hinders colonization. Gram-negative pathogens, A. baumannii and P. mirabilis co-localize with Fg during urinary catheterization; however, the bacterial factors and any mode of interaction have not been described, to inventors' knowledge. Interaction of E. coli and K. pneumoniae with Fg during CAUTI has not been described.
[0171] Type 1 pili, a chaperon-usher pathway (CUP) pili, allows pathogens to colonize the bladder urothelium by binding to mannosylated receptors on the urothelial surface through the tip adhesin FimH. Furthermore, other CUP pili including the P pili, important for pyelonephritis, and the Fml pilus, important for colonizing inflamed bladder urothelium, bind specifically to sugar residues Gal1-4Gal in glycolipids and Gal(1-3)GalNAc in glycoproteins, respectively. Interestingly, Fg is highly glycosylated, containing a wide variety of sugar residues including mannose, N-acetyl glucosamine, fucose, galactose, and N-acetylneuraminic acid. Without wishing to be bound to any particular theory, the glycosylation in Fg may be recognized by CUP pili for colonization. Furthermore, A. baumannii CUP1 and CUP2 pili are essential for CAUTI, this together with its interactions with Fg in vivo, suggests that these pili may play a role in Fg interaction. Similarly, P. aeruginosa also encodes CUP pili, CupA, CupB, CupC and CupD, which are important for biofilm formation. Furthermore, C. albicans has several adhesins, ALS1, ALS3, and ALS9, which have a conserved peptide binding cavity shown to bind to Fg -chain (Hoyer & Cota, 2016).
[0172] Inhibition of initial uropathogen binding reduces colonization and biofilm formation on urinary catheter surfaces and prevent subsequent CAUTI. To prevent surface binding, a variety of modified surfaces impregnated with antimicrobial or bacteriostatic compounds have been generated and, have proven to reduce microbial binding in vitro but not in vivo. Without wishing to be bound to any particular theory, in vitro studies do not efficiently mimic the complexities of the in vivo environment, for example; 1) Growth media: the majority of the in vitro studies use laboratory rich or defined culture media, and laboratory media does not recapitulate the catheterized bladder environment that pathogens encounter. Specifically, urine culture conditions activate different bacterial transcriptional profiles than when grown in defined media, which may affect microbial persistence and survival. 2) Host factors: host-secreted proteins are released into the bladder due to catheter-induced physical damage and subsequent inflammation. Without wishing to be bound to any particular theory, these proteins are deposited on the catheter surface and can hinder the release of antimicrobials or block interaction of antimicrobials with the pathogen. As has been observed with Fg deposition, host-protein deposition is not uniform, which may lead to antimicrobial release or pathogen-antimicrobial agent interaction at a sub-inhibitory concentrations. Consequently, these interactions can contribute to the development of multidrug-resistance among uropathogens.
[0173] Based on the role of deposited host-proteins in promoting microbial colonization, antifouling catheter coatings present a better approach to decreasing CAUTI prevalence rather than using biocidal or biostatic compounds, such as antibiotics, that promote resistance. Antifouling coatings are made from polymers and have shown resistance to protein deposition; however, these coatings can become unstable over time and be difficult to produce. However, antifouling coatings made from polymers antifouling coating can be challenging to produce in large quantities. Furthermore, molecular degradation and desorption can affect the integrity and function of the hydration shells over time.
[0174] Most reports on the use of purely antifouling coatings to combat CAUTI have shown successful reduction in bacterial colonization in vitro, but not in vivo. Many antifouling coatings are optimized to target bacterial adhesion, as it is understood that the first stage of biofilm development is bacterial attachment to a surface. However, in a complex environment such as the in vivo bladder, the first change to the catheter surface is the adhesion of a complex set of host-generated proteins and biological molecules, generally referred to as a conditioning film, which can mask the surface. Yet studies on catheter coatings to-date have rarely focused on the role of the host in infection establishment; namely, the host-secreted proteins. Data presented herein suggest that this missing element may at least partly explain the differing results seen for most antifouling catheter treatments in vitro vs in vivo.
[0175] This example used a clinically relevant silicone oil to create a simple liquid-infused polymer that was not only bacteria-resistant but also protein-resistant, filling in the missing link between in vitro and in vivo work, the conditioning film. Furthermore, lack of an exacerbated inflammation response seen in the results shows reduced capsule formation in implants in which the liquid layer has been mechanically removed or stripped from the surface of the silicone substrate, suggesting that the use of a substrate infused with a silicone oil and not having a free overlayer of silicone oil conveys additional anti-inflammatory benefits.
[0176] A deeper understanding of the pathogenesis of CAUTI is critical to moving beyond current developmental roadblocks and create more efficient intervention strategies. Infusion of silicone with an immiscible liquid and resulting in a coating that does not form an overlayer significantly decreases Fg deposition and microbial binding as shown herein by using in vitro conditions that more thoroughly recapitulate the catheterized bladder environment. Importantly, in vitro results presented herein were confirmed in vivo using a mouse model of CAUTI as described herein. Data presented herein shows that LIS-catheters are refractory to bacterial colonization without targeting microbial survival, which often leads to antimicrobial resistance, and thus holds tremendous potential for the development of lasting and effective CAUTI treatments. These types of technologies are needed to achieve better public health by decreasing healthcare-associated infections and promoting long-term wellness.
Materials and Methods:
Mouse Infection Models
[0177] Mice used in this study were 6-week-old female wild-type C57BL/6 mice purchased from Jackson Laboratory and The National Institute of Cancer Research. Mice were subjected to transurethral implantation and inoculated as previously described (Conover, Flores-Mireles, Hibbing, Dodson, & Hultgren, 2015). Briefly, mice were anesthetized by inhalation of isoflurane and implanted with a 6-mm-long UM-silicone or LIS-catheter. Mice were infected immediately following catheter implantation with 50 l of 210.sup.7 CFU/mL in PBS introduced into the bladder lumen by transurethral inoculation (unless otherwise noted (ST1). For all mouse experiments microbes were grown in their corresponding media (ST1). To harvest the catheters and organs, mice were sacrificed at 24 hrs post infection by cervical dislocation after anesthesia inhalation; the silicone catheter, bladder, kidneys, heart and spleen were aseptically harvested. Catheters were either subjected to sonication (Branson, Ultrasonic Bath) for CFU enumeration analysis, fixed for imaging via standard IF procedure described above, or sent for proteomic analysis as described using nonimplanted catheters as controls. Bladders for immunofluorescence and histology were fixed and processed as described below. Kidneys, Spleens and Hearts were all used for CFU analysis. The University of Notre Dame Institutional Animal Care and Use Committee approved all mouse infections and procedures as part of protocol number 18-08-4792MD and #22-016971. All animal care was consistent with the Guide for the Care and Use of Laboratory Animals from the National Research Council.
Bladder IHC and H&E Staining of Mouse Bladders
[0178] Mouse bladders were fixed in formalin overnight, before being processed for sectioning and staining as described in Walker et al., 2017. Briefly, bladder sections were deparaffinized, rehydrated, and rinsed with water. Antigen retrieval was accomplished by boiling the samples in Na-citrate, washing in water, and then incubating in PBS three times. Sections were then blocked (1PBS, 1.5% BSA, 0.1% Sodium Azide), washed in PBS, and incubated with appropriate primary antibodies overnight at 4 C. Next, sections were washed with PBS, incubated with secondary antibodies for 2 h at room temperature (RT), and washed once more in PBS prior to Hoechst dye staining. Hematoxylin and Eosin (H&E) stain for light microscopy was done by the CORE facilities at the University of Notre Dame (ND CORE). All imaging was done using a Zeiss inverted light microscope (Carl Zeiss, Axio Observer). Zen Pro (Carl Zeiss, Thornwood, NY) and ImageJ software were used to analyze the images.
Human Urine Collection
[0179] Human urine was collected and pooled from at least two healthy female donors between 20-40 years of age. Donors had no history of kidney disease, diabetes or recent antibiotic treatment. Urine was sterilized using a 0.22 m filter (Sigma Aldrich) and pH 6.0-6.5. When supplemented with Bovine Serum Albumin (BSA) (VWR Lifesciences), urine was filter sterilized again following BSA addition. All participants signed an informed consent form and protocols were approved by the local Internal Review Board at the University of Notre Dame under study #19-04-5273.
Microbial Growth Conditions in Supplemented Urine
[0180] E. faecalis, and C. albicans were grown static for 5 hrs in 5 mL of respective media (Table 2) followed by static overnight culture in human urine supplemented with 20 mg/mL BSA (urine BSA20). E. coli, K. pneumoniae, P. mirabilis, A. baumanii and P. aeruginosa were grown 5 hrs shaking at 37 C. in LB then static for 24 hours, supplemented into fresh urine BSA for another 24 hours static (224 hrs) in urine BSA20. All cultures were washed in PBS (Sigma) 3 times and resuspended in assay appropriate media.
Silicone Disk Preparation
[0181] 8 mm disks of UM-silicone (Nalgene 50 silicone tubing, Brand Products) or LIS were cut using a leather hole punch. UM disks were washed 3 times in PBS and air dried. LIS disks were stored in filter sterilized modifying liquid at RT. Disks were skewered onto needles (BD) to hold them in place and put in 5 mL glass tubes (Thermo Scientific) or placed on the bottom of 96 well plate wells (Fisher Scientific) (UM silicone only). Plates and glass tubes were UV sterilized for >30 min prior to use.
Protein Binding Assays
[0182] Human fibrinogen free from plasminogen and von Willebrand factor (Enzyme Research Laboratory #FB3) was diluted to 150 ug/mL in PBS. 500 uL of 150 ug/mL Fg was added to each disk in glass tubes, sealed, and left over night at 4 C. Disks were then processed according to standard immunofluorescence (IF) procedure as described in Colomer-Winter et al., 2019. Briefly, disks were washed 3 times in PBS, fixed with 10% Neutralized formalin (Leica), blocked, and stained using Goat anti-Fg primary antibody (Sigma) (1:1000) and Donkey anti-Goat IRD800 secondary antibody (Invitrogen) (1:1000). Disks were then dried over night at 4 C. and imaged on an Odyssey Imaging System (LI-COR Biosciences) to examine the infrared signal. Intensities for each catheter piece were normalized against a negative control and then made relative to the pieces coated with Fg which was assigned to 100%. Images were processed using Image Studio Software (LI-COR, Lincoln, NE) Microsoft Excel and graphed on GraphPad Prism (GraphPad Software, San Diego, CA).
Microbial Binding Assays
[0183] For assessing the effect of protein deposition on microbial binding, 100 uL of 150 ug/mL Human Fg, 100 L of 150 g/mL BSA, or 100 L of PBS were incubated on UM-silicone disks in 96 well plates overnight at 4 C. The following day disks were washed 3 times with PBS followed by a 2 hr RT incubation in 100 uL of urine containing microbes at a concentration of 10{circumflex over ()}8 CFU/mL. For assessing microbial binding to UM-silicone versus LIS, 500 uL of microbe containing media was added to prepared disks in glass tubes. Standard IF procedure was then followed as described herein using goat anti-Fg and rabbit anti-microbe primary antibodies (1:1000) (see ST1 for details). Secondary antibodies used were Donkey anti-Goat IRD800 and Donkey anti-Rabbit IRD680 (1:5000). Quantification of binding was done using ImageStudio Software (LI-COR). Intensities for each catheter piece were normalized against a negative control and then made relative to the pieces coated with Fg which was assigned to 100%.
Weight Measurement of Silicone Tubes and Tygon Tubes Versus Infusion Time
[0184] Five samples of 20 cm Tygon tube (14-171-219, Saint-Gobain Tygon S3 3603 Flexible Tubings, Fisher Scientific, USA) or silicone tube (8060-0030, Nalgene 50 Platinum-cured Silicone Tubing, Thermo Scientific, USA) were utilized in weight measurement. Weight of the tubes prior to infusion were measured with an analytical balance (AL204, Analytical Balance, Mettler Toledo, Germany), results were marked as 0 h infused in silicone oil. After the measurement of the initial weights, the tubes were incubated with silicone oil (DMS-T15, Polydimethylsiloxane, trimethylsiloxy, 50 cSt, GelestSInc., USA) until designated time points. For each time point, tubes were removed from the oil with forceps and held vertically for 30 seconds for the excess silicone oil to flow out of the tube. The bottoms of the tubes were then gently dabbed with Kimwipes (Kimwipe, Kimberly-Clark Corp., USA), and then subjected to weight measurement. After measurement, the tubes were placed back into silicone oil until the next time point. Tubes were measured every 3 hrs for the first 2 days; every 6 hrs from day 3 to day 6; and every 24 hrs from day 6 and onwards. Measurements were taken until data showed no significant increase, and that the plateau trendline consist of at least 3 data points.
Weight Measurement of Mouse Catheters Versus Infusion Time
[0185] Five samples of 20 cm mouse catheter (SIL 025, RenaSil Silicone Rubber Tubing, Braintree Scientific, Inc., USA) were utilized in weight measurement. Weight of the tubes prior to infusion were measured with an analytical balance, results were marked as 0 min infused in silicone oil. After the measurement of the initial weights, the tubes were incubated with silicone oil until designated time points. For each time point, catheters were removed from the oil with forceps, a Kimwipes was immediately pressed against the bottom of the catheters to remove the excess silicone oil via capillary action. After the excess oil was drained, catheters were then subjected to weight measurement. The catheters were placed back into silicone oil until the next time point. Catheters were measured every 1 minute for the first 5 minutes of the experiment; every 2 minutes from 5-15 minutes; and every 5 minutes from 15 minutes and onwards. Measurements were taken until data showed no significant increase, and that the plateau trendline consist of at least 3 data points.
Parameter Measurement of Silicone Tube Before and After Infusion
[0186] The length, inner diameter and outer diameter of the silicone tubes were measured before silicone oil infusion and after complete infusion (after incubating with silicone oil for >7 days). All parameters were measured using a digital caliper (06-664-16, Fisherbrand Traceable Digital Calipers, Fisher Scientific, USA).
Parameter Measurement of Mouse Catheters Before and After Infusion
[0187] The length, inner diameter, and outer diameter of the mouse catheters were measured before silicone oil infusion and after complete infusion (after incubating with silicone oil for >30 minutes). The length of the mouse catheter was measured using a digital caliper. Photos of the tube openings of the catheters and a scale of known length were taken. The inner and outer diameter were then estimated via ImageJ. Percentage weight change of Tygon tube, silicone tube and mouse catheters were calculated based on the formula below:
Proteomic Analysis of Mouse Catheters
[0188] Five mice were catheterized with a LIS-catheter, 4 mice were catheterized with an UM-catheter and catheters harvested 24 hrs after infection with E. faecalis OG1RF. Harvested catheters were put into 100 L of SDS buffer (100 mM Tris HCl pH-8.8, 10 mM DTT and 2% SDS), then vortexed for 30 sec, heated for 5 min at 90 C., sonicated for 30 min and the process repeated once more. Samples were sent to the Mass Spectrometry and Proteomics Facility at Notre Dame (MSPF) for proteomic analysis. Proteins were further reduced in DTT, alkylated and digested with trypsin using Suspension Trap and protocols (Zougman, Selby, & Banks, 2014) nLC-MS-MS/MS was performed essentially as described in (Sanchez et al., 2020) on a Q-Exactive instrument (Thermo).
[0189] Proteins were identified and quantified using MaxLFQ (Label Free Quantification) within MaxQuant and cutoff at a 1% FDR (Cox & Mann, 2008). This generated a total of 8 data records from UM-catheters and 10 from LIS-catheters. Data reduction was performed by removing contaminants proteins. Protein abundance for each catheter type was of 105 then calculated by summing the LFQ intensity of proteins which comprised 95% of the total abundance on the catheters. Strict filtering criteria of at least 2 replicates with technical replication from the UM-catheters and 3 replicates with technical duplication from the LIS-catheters were required to keep an identification. Abundance of the reduced proteins was plotted using Graph Pad Prism. Statistical significance was tested using a Mann-Whitney U test. A volcano plot was created using the ranked mean difference for each protein and log of calculated P-values with an alpha=0.05.
Statistical Analysis
[0190] Unless otherwise stated, in the current example, data from at least 3 experiments were pooled for each assay. Significance of experimental results were assessed by Mann-Whitney U test using GraphPad Prism, version 7.03 (GraphPad Software, San Diego, CA). Significance values on graphs are *p0.05, **p0.01, ***p0.001 and ****p0.00001.
Antibodies Used in this Study
[0191] Primary antibodies against microbial pathogens used in the study are listed in Table 2. Primary antibodies against non-pathogens used are provided as follows: Fg, Goat anti-Fibrinogen and neutrophils, Rat anti-Ly6G.
[0192] Secondary antibodies used for IF in the study: IRDye 800CW donkey anti goat (LI-COR) and IRDye 680LT Donkey anti-rabbit (LI-COR). Secondary antibodies for IHC; Donkey anti-goat (Life Technologies Corporation), Donkey anti-rabbit (Invitrogen), Donkey anti-mouse (Invitrogen) and Donkey anti-rat (Invitrogen).
VII. Experimental Example 2
[0193] Described herein is an embodiment of a method of modifying catheters. In certain embodiments, the methods and devices described significantly reduce deposition of Fg on the surface, while allowing for adhesion of non-Fg proteins.
Catheter Modification Protocol
[0194] Inventors developed a surface treatment that significantly reduces deposition of Fg on silicone catheters in vivo while significantly increasing the adhesion of non-Fg proteins. The coatings are created on commercially available catheters by submerging the entire catheter in a free silicone liquid with the capacity to diffuse throughout the polymer until equilibrium is reached as shown in
[0195]
[0196]
Mechanism for Altered Adhesion
[0197] Without wishing to be bound to any particular theory, the surface of polydimethylsiloxane (PDMS) presents a locally heterogeneously charged surface to which proteins such as fibrinogen (Fg) and serum albumin adsorb. The semi-ionic nature of siloxane molecules is caused by difference in electronegativity between the silicone and oxygen atoms. Introducing unbound siloxane molecules into the system (e.g., via a silicone oil) allows the new compound liquid/solid material to reach charge equilibrium, as the free molecules are drawn via attraction forces to regions where their own ionic charges cancel out those of the cross-linked solid polymer as shown in
[0198]
[0199] The use of free siloxane molecules, which can migrate dynamically within the polymer bulk, allows for the treatment of any commercial silicone mixture, regardless of specific composition, as the free molecules will naturally adapt to the specific charge distribution created by the use of different additives, cross-linkers, or curing protocols.
VIII. Experimental Example 3
[0200] Among other things, described herein are changes of silicone substrates under different infusion conditions.
[0201]
[0202] For fully impregnated samples, the silicone samples were immersed in silicone oil and removed from the silicone oil after the samples were substantially fully impregnated with silicone oil. The free liquid overlayer of silicone oil was not removed from the surface of the samples, as is shown in the figure.
[0203] For the overlayer stripped samples, the silicone samples were immersed in silicone oil and removed from the silicone oil after the samples were substantially fully impregnated (fully infused) with silicone oil. The free liquid overlayer of silicone oil was removed mechanically from the surface of each of the samples as shown in
[0204] % Q.sub.max refers to various degrees of partial impregnation of silicone substrates. The silicone samples were immersed in silicone oil for varying periods of time and removed from the silicone oil after the sample was infused with silicone oil at the desired % Q.sub.max.
[0205]
[0206] Among other things, these results demonstrate that the two different tested methods of removing the excess free overlayer of silicone oil (i.e., overlayer stripping and partial infusion) are fundamentally different from the fully infused samples with a free overlayer of silicone oil.
[0207] Continuing with the experimental examples,
[0208] These results demonstrate that the two different methods of removing the excess overlayer (i.e., overlayer stripping and partial impregnation) do significantly reduce the amount of free silicone liquid that can be physically removed from the surface. For example, after mechanically stripping the overlayer, fully or partially impregnated silicone samples experience less loss of oil than samples which have not been stripped of silicone oil.
[0209]
[0210] These results demonstrate that the two different methods of removing excess free silicone overlayer (i.e., overlayer stripping and partial impregnation) result in a significant reduction of the amount of protein and E. faecalis bacteria adhesion as compared to controls that did not undergo infusion with silicone oil.
IX. Experimental Example 4
[0211] Among other things, the present example shows differences between PDMS catheters which have not been infused with silicone oil, PDMS catheters which have been infused with silicone oil (LIS-catheters), and LIS-catheters that have had the overlayer stripped.
[0212] Overlayer stripping removes free silicone oil from the surface of PDMS substrates, which is shown in
[0213]
[0214] Once prepared, any excess dyed surface oil was removed by passing the samples through an air/water interface of a 10 mL volume of DI water 10 times in succession. A 1 ml aliquot of toluene (108-883, Toluene anhydrous, Alfa Aesar, USA) was then added to the DI water containing the removed silicone oil, manually shaken for 1 minute, then left to settle for at least 1 minute to allow the tolune and water phases to separate. The top layer was carefully extracted and placed in a glass cuvette for spectrophotometer (840-277000, GENESYS 30 Visible Spectrophotometer, Thermo Fisher, USA) measurement. The absorbance of the samples was measured at 2 nm intervals within the 350-650 nm range, with the presence of a peak indicating the presence of dyed silicone oil that had been removed from the catheter segment. All results were standardized to the size of the sample catheter segment in mm and reported as either L of oil or the percentage of total amount of oil infused into the sample oil lost to the DI water per mm of catheter length.
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223] Fully infused LIS-catheter sections with the overlayer stripped were comparable in both tilt angle and droplet velocity to a fully infused LIS-catheter section with an intact overlayer as shown in
[0224]
[0225]
[0226]
[0227] The protocol for measuring droplet sliding velocity is described as follows. A section of catheter tubing being tested (2 cm, length of 8060-0030, Nalgene 50 Platinum-cured Silicone Tubing, Thermo Scientific, USA) was placed on a tilt stage at 30. A digital angle gauge (AccuMASTER 2 in 1 Magnetic Digital Level and Angle Finder, Calculated Industries) was affixed to the tilt stage to ensure the angle is maintained. A 20 l droplet containing water, crystal violet, or bromophenol blue was introduced into the tubing's lumen using a pipette. The time taken for the droplet to travel from the beginning to the end of the tube was measured. To ensure precise time measurement, a camera was utilized to record the entire experiment for a frame-by-frame analysis.
[0228] The results in the panels show a difference in average sliding speed for non-infused PMDS substrates (i.e., substrates with a 0 Qmax) for both positively charged and negatively charged droplets as compared to the neutrally charged droplets. At the lowest level of infusion (i.e., 50%-64% Qmax), the difference in sliding speed between positively charged droplets, negatively charged droplets, and neutrally disappears, which suggests that charge neutralization is playing a role in the functionality of LIS-catheters.
X. Experimental Example 5
[0229] Among other things, the present example shows differences between liquid infused substrate (LIS) PDMS catheters (LIS-catheters) as compared to PDMS catheters that were unmodified (UM). The silicone oil overlayer of the LIS-catheters were stripped in this experiment as the catheters were inserted into mice bladders. LIS-catheters described in this example have been infused with a silicone oil. In particular, the present example concerns differences in E. coli catheter-associated urinary tract infections (UTIs) and systemic dissemination during prolonged urinary catheterization.
[0230] The inventors tested the ability of liquid infused substrate catheters (LIS-catheters) to reduce uropathogenic E. coli colonization in bladders as compared to PDMS catheters that were unmodified. The systemic dissemination of E. coli at 1, 3, and 7 days post infection and catheterization was tested in animal models. For this experiment, mice were catheterized with either an UM- or LIS-catheter and challenged with 210.sup.7 CFU of uropathogenic E. coli. An hour before catheterizing the mice, the LIS-catheters were removed from the silicon oil solution, the remaining silicon oil was drained, and catheters were let to dry. Furthermore, if any remaining the overlayer was present that was stripped away during the passage of the LIS-catheter though the urethra. At 1, 3, and 7 days post-infection, bladders and catheters were harvested and assessed for microbial burden by CFU (colony forming unit) enumeration or fixed for staining. Kidneys, spleens and hearts were collected to determine microbial burden.
[0231] These data demonstrate that LIS-catheters (labeled as LIS in
[0232] Elements of different implementations described herein may be combined to form other implementations not specifically set forth above. Elements may be left out of the processes and devices described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions of devices or methods described herein.
[0233] Throughout the description, where devices or systems are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are apparatus, and systems of the described technology that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the described technology that consist essentially of, or consist of, the recited processing steps.
[0234] While the described technology has been particularly shown and described with reference to specific embodiments, it should be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the described technology.
INCORPORATION BY REFERENCE
[0235] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
EQUIVALENTS
[0236] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.